1
|
Dussiau C, Comont T, Knosp C, Vergnolle I, Bravetti C, Canali A, Houvert A, Largeaud L, Daveaux C, Zaroili L, Friedrich C, Boussaid I, Zalmai L, Almire C, Rauzy O, Willems L, Birsen R, Bouscary D, Fontenay M, Kosmider O, Chapuis N, Vergez F. Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms. Leukemia 2024; 38:1131-1142. [PMID: 38575672 DOI: 10.1038/s41375-024-02234-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Revised: 03/15/2024] [Accepted: 03/19/2024] [Indexed: 04/06/2024]
Abstract
Myelodysplastic neoplasms (MDS) are characterized by clonal evolution starting from the compartment of hematopoietic stem and progenitors cells (HSPCs), leading in some cases to leukemic transformation. We hypothesized that deciphering the diversity of the HSPCs compartment may allow for the early detection of an emergent sub-clone that drives disease progression. Deep analysis of HSPCs repartition by multiparametric flow cytometry revealed a strong disorder of the hematopoietic branching system in most patients at diagnosis with different phenotypic signatures closely related to specific MDS features. In two independent cohorts of 131 and 584 MDS, the HSPCs heterogeneity quantified through entropy calculation was decreased in 47% and 46% of cases, reflecting a more advanced state of the disease with deeper cytopenias, higher IPSS-R risk and accumulation of somatic mutations. We demonstrated that patients with lower-risk MDS and low CD34 + CD38+HSPCs entropy had an adverse outcome and that this parameter is as an independent predictive biomarker for progression free survival, leukemia free survival and overall survival. Analysis of HSPCs repartition at diagnosis represents therefore a very powerful tool to identify lower-risk MDS patients with a worse outcome and valuable for clinical decision-making, which could be fully integrated in the MDS diagnostic workflow.
Collapse
Affiliation(s)
- Charles Dussiau
- Assistance Publique-Hôpitaux de Paris. Centre-Université Paris Cité, Service d'hématologie biologique, Hôpital Cochin, Paris, France
- Université Paris Cité, Institut Cochin, CNRSUMR8104, INSERM U1016, Paris, France
| | - Thibault Comont
- Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Service de Médecine Interne, Toulouse, France
- Université Toulouse III Paul Sabatier, Toulouse, France
- Cancer Research Center of Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France
| | - Camille Knosp
- Université Paris Cité, Institut Cochin, CNRSUMR8104, INSERM U1016, Paris, France
| | - Inès Vergnolle
- Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Laboratoire d'Hématologie, Toulouse, France
| | - Clotilde Bravetti
- Université Paris Cité, Institut Cochin, CNRSUMR8104, INSERM U1016, Paris, France
| | - Alban Canali
- Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Laboratoire d'Hématologie, Toulouse, France
| | - Amandine Houvert
- Université Paris Cité, Institut Cochin, CNRSUMR8104, INSERM U1016, Paris, France
| | - Laetitia Largeaud
- Université Toulouse III Paul Sabatier, Toulouse, France
- Cancer Research Center of Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France
- Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Laboratoire d'Hématologie, Toulouse, France
| | - Christian Daveaux
- Université Paris Cité, Institut Cochin, CNRSUMR8104, INSERM U1016, Paris, France
| | - Laila Zaroili
- Université Paris Cité, Institut Cochin, CNRSUMR8104, INSERM U1016, Paris, France
| | - Chloé Friedrich
- Assistance Publique-Hôpitaux de Paris. Centre-Université Paris Cité, Service d'hématologie biologique, Hôpital Cochin, Paris, France
- Université Paris Cité, Institut Cochin, CNRSUMR8104, INSERM U1016, Paris, France
| | - Ismaël Boussaid
- Assistance Publique-Hôpitaux de Paris. Centre-Université Paris Cité, Service d'hématologie biologique, Hôpital Cochin, Paris, France
- Université Paris Cité, Institut Cochin, CNRSUMR8104, INSERM U1016, Paris, France
| | - Loria Zalmai
- Assistance Publique-Hôpitaux de Paris. Centre-Université Paris Cité, Service d'hématologie biologique, Hôpital Cochin, Paris, France
| | - Carole Almire
- Assistance Publique-Hôpitaux de Paris. Centre-Université Paris Cité, Service d'hématologie biologique, Hôpital Cochin, Paris, France
| | - Odile Rauzy
- Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Service de Médecine Interne, Toulouse, France
- Université Toulouse III Paul Sabatier, Toulouse, France
- Cancer Research Center of Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France
| | - Lise Willems
- Université Paris Cité, Institut Cochin, CNRSUMR8104, INSERM U1016, Paris, France
- Assistance Publique-Hôpitaux de Paris. Centre-Université Paris Cité, Service d'hématologie clinique, Hôpital Cochin, Paris, France
| | - Rudy Birsen
- Université Paris Cité, Institut Cochin, CNRSUMR8104, INSERM U1016, Paris, France
- Assistance Publique-Hôpitaux de Paris. Centre-Université Paris Cité, Service d'hématologie clinique, Hôpital Cochin, Paris, France
| | - Didier Bouscary
- Université Paris Cité, Institut Cochin, CNRSUMR8104, INSERM U1016, Paris, France
- Assistance Publique-Hôpitaux de Paris. Centre-Université Paris Cité, Service d'hématologie clinique, Hôpital Cochin, Paris, France
| | - Michaela Fontenay
- Assistance Publique-Hôpitaux de Paris. Centre-Université Paris Cité, Service d'hématologie biologique, Hôpital Cochin, Paris, France
- Université Paris Cité, Institut Cochin, CNRSUMR8104, INSERM U1016, Paris, France
| | - Olivier Kosmider
- Assistance Publique-Hôpitaux de Paris. Centre-Université Paris Cité, Service d'hématologie biologique, Hôpital Cochin, Paris, France
- Université Paris Cité, Institut Cochin, CNRSUMR8104, INSERM U1016, Paris, France
| | - Nicolas Chapuis
- Assistance Publique-Hôpitaux de Paris. Centre-Université Paris Cité, Service d'hématologie biologique, Hôpital Cochin, Paris, France.
- Université Paris Cité, Institut Cochin, CNRSUMR8104, INSERM U1016, Paris, France.
| | - François Vergez
- Université Toulouse III Paul Sabatier, Toulouse, France
- Cancer Research Center of Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France
- Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Laboratoire d'Hématologie, Toulouse, France
| |
Collapse
|
2
|
Rombaut D, Lefèvre C, Rached T, Bondu S, Letessier A, Mangione RM, Farhat B, Lesieur-Pasquier A, Castillo-Guzman D, Boussaid I, Friedrich C, Tourville A, De Carvalho M, Levavasseur F, Leduc M, Le Gall M, Battault S, Temple M, Houy A, Bouscary D, Willems L, Park S, Raynaud S, Cluzeau T, Clappier E, Fenaux P, Adès L, Margueron R, Wassef M, Alsafadi S, Chapuis N, Kosmider O, Solary E, Constantinou A, Stern MH, Droin N, Palancade B, Miotto B, Chédin F, Fontenay M. Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation. Nat Commun 2024; 15:3016. [PMID: 38589367 PMCID: PMC11001894 DOI: 10.1038/s41467-024-46547-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Accepted: 02/29/2024] [Indexed: 04/10/2024] Open
Abstract
Myelodysplastic syndromes (MDS) with mutated SF3B1 gene present features including a favourable outcome distinct from MDS with mutations in other splicing factor genes SRSF2 or U2AF1. Molecular bases of these divergences are poorly understood. Here we find that SF3B1-mutated MDS show reduced R-loop formation predominating in gene bodies associated with intron retention reduction, not found in U2AF1- or SRSF2-mutated MDS. Compared to erythroblasts from SRSF2- or U2AF1-mutated patients, SF3B1-mutated erythroblasts exhibit augmented DNA synthesis, accelerated replication forks, and single-stranded DNA exposure upon differentiation. Importantly, histone deacetylase inhibition using vorinostat restores R-loop formation, slows down DNA replication forks and improves SF3B1-mutated erythroblast differentiation. In conclusion, loss of R-loops with associated DNA replication stress represents a hallmark of SF3B1-mutated MDS ineffective erythropoiesis, which could be used as a therapeutic target.
Collapse
Affiliation(s)
- David Rombaut
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
- Laboratoire d'excellence du Globule Rouge GR-Ex, Université Paris Cité, Paris, France
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France
| | - Carine Lefèvre
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
- Laboratoire d'excellence du Globule Rouge GR-Ex, Université Paris Cité, Paris, France
| | - Tony Rached
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Sabrina Bondu
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Anne Letessier
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
| | | | - Batoul Farhat
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Auriane Lesieur-Pasquier
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Daisy Castillo-Guzman
- Department of Molecular and Cellular Biology and Genome Center, University of California, Davis, CA, USA
| | - Ismael Boussaid
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France
| | - Chloé Friedrich
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France
| | - Aurore Tourville
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Magali De Carvalho
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Françoise Levavasseur
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Marjorie Leduc
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Platform Proteom'IC, Université Paris Cité, Institut Cochin, Paris, France
| | - Morgane Le Gall
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Platform Proteom'IC, Université Paris Cité, Institut Cochin, Paris, France
| | - Sarah Battault
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Marie Temple
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France
| | - Alexandre Houy
- Institut Curie, PSL Research University, Sorbonne University, INSERM U830, DNA repair and uveal melanoma, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France
| | - Didier Bouscary
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Clinical Department of Hematology, Paris, France
| | - Lise Willems
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Clinical Department of Hematology, Paris, France
| | - Sophie Park
- Department of Hematology, Centre Hospitalier Universitaire, Université de Grenoble Alpes, Grenoble, France
| | - Sophie Raynaud
- Laboratory of Hematology, Université Côte d'Azur, Centre Hospitalier Universitaire, Nice, France
| | - Thomas Cluzeau
- Clinical Department of Hematology, Université Côte d'Azur, Centre Hospitalier Universitaire, Nice, France
| | - Emmanuelle Clappier
- Assistance Publique-Hôpitaux de Paris.Nord-Université Paris Cité, Saint-Louis Hospital, Laboratory of Hematology, Paris, France
| | - Pierre Fenaux
- Assistance Publique-Hôpitaux de Paris.Nord-Université Paris Cité, Saint-Louis Hospital, Service Hématologie Séniors, Paris, France
| | - Lionel Adès
- Assistance Publique-Hôpitaux de Paris.Nord-Université Paris Cité, Saint-Louis Hospital, Service Hématologie Séniors, Paris, France
| | - Raphael Margueron
- Institut Curie, Paris Sciences Lettres Research University, Sorbonne University, INSERM U934, UMR3215, Paris, France
| | - Michel Wassef
- Institut Curie, Paris Sciences Lettres Research University, Sorbonne University, INSERM U934, UMR3215, Paris, France
| | - Samar Alsafadi
- Institut Curie, PSL Research University, Sorbonne University, INSERM U830, DNA repair and uveal melanoma, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France
| | - Nicolas Chapuis
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France
| | - Olivier Kosmider
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France
| | - Eric Solary
- Institut Gustave Roussy, INSERM 1287, Université Paris Saclay, Villejuif, France
| | - Angelos Constantinou
- Institut de Génétique Humaine, Centre National de la Recherche Scientifique, Université de Montpellier, Montpellier, France
| | - Marc-Henri Stern
- Institut Curie, PSL Research University, Sorbonne University, INSERM U830, DNA repair and uveal melanoma, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France
| | - Nathalie Droin
- Institut Gustave Roussy, INSERM 1287, Université Paris Saclay, Villejuif, France
| | - Benoit Palancade
- Université Paris Cité, CNRS, Institut Jacques Monod, Paris, France
| | - Benoit Miotto
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
| | - Frédéric Chédin
- Department of Molecular and Cellular Biology and Genome Center, University of California, Davis, CA, USA
| | - Michaela Fontenay
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France.
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France.
- Laboratoire d'excellence du Globule Rouge GR-Ex, Université Paris Cité, Paris, France.
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France.
| |
Collapse
|
3
|
Choquet S, Soussain C, Azar N, Morel V, Metz C, Ursu R, Waultier-Rascalou A, di Blasi R, Houot R, Souchet L, Roos-Weil D, Uzunov M, Quoc SN, Jacque N, Boussen I, Gauthier N, Ouzegdouh M, Blonski M, Campidelli A, Ahle G, Guffroy B, Willems L, Corvilain E, Barrie M, Alcantara M, le Garff-Tavernier M, Psimaras D, Weiss N, Baron M, Bravetti C, Hoang-Xuan K, Davi F, Shor N, Alentorn A, Houillier C. CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network. Am J Hematol 2024. [PMID: 38586986 DOI: 10.1002/ajh.27316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Revised: 02/24/2024] [Accepted: 03/26/2024] [Indexed: 04/09/2024]
Abstract
The prognosis of relapsed primary central nervous system lymphoma (PCNSL) remains dismal. CAR T-cells are a major contributor to systemic lymphomas, but their use in PCNSL is limited. From the LOC network database, we retrospectively selected PCNSL who had leukapheresis for CAR-T cells from the third line of treatment, and, as controls, PCNSL treated with any treatment, at least in the third line and considered not eligible for ASCT. Twenty-seven patients (median age: 68, median of three previous lines, including ASCT in 14/27) had leukapheresis, of whom 25 received CAR T-cells (tisa-cel: N = 16, axi-cel: N = 9) between 2020 and 2023. All but one received a bridging therapy. The median follow-up after leukapheresis was 20.8 months. The best response after CAR-T cells was complete response in 16 patients (64%). One-year progression-free survival from leukapheresis was 43% with a plateau afterward. One-year relapse-free survival was 79% for patients in complete or partial response at CAR T-cell infusion. The median overall survival was 21.2 months. Twenty-three patients experienced a cytokine release syndrome and 17/25 patients (68%) a neurotoxicity (five grade ≥3). The efficacy endpoints were significantly better in the CAR T-cell group than in the control group (N = 247) (median PFS: 3 months; median OS: 4.7 months; p < 0.001). This series represents the largest cohort of PCNSL treated with CAR T-cells reported worldwide. CAR T-cells are effective in relapsed PCNSL, with a high rate of long-term remission and a reassuring tolerance profile. The results seem clearly superior to those usually observed in this setting.
Collapse
Affiliation(s)
- Sylvain Choquet
- Service d'Hématologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Carole Soussain
- Service d'Hématologie Clinique, Institut Curie, site de Saint Cloud, France and INSERM U932, Institut Curie, PSL Research University, Paris, France
| | - Nabih Azar
- Service d'Hématologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Véronique Morel
- Service d'Hématologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Carole Metz
- Unité REQPHARM, pharmacie à usage intérieur, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France
| | - Renata Ursu
- Service de Neurologie, Université de Paris Cité, APHP, Hôpital Saint Louis, Paris, France
| | | | - Roberta di Blasi
- Service d'Oncohématologie, Université de Paris Cité, APHP, Hôpital Saint Louis, Paris, France
| | - Roch Houot
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, UMR U1236, INSERM Université de Rennes, Etablissement Français du Sang, Rennes, France
| | - Laetitia Souchet
- Service d'Hématologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Damien Roos-Weil
- Service d'Hématologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Madalina Uzunov
- Service d'Hématologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Stéphanie Nguyen Quoc
- Service d'Hématologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Nathalie Jacque
- Service d'Hématologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Inès Boussen
- Service d'Hématologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Nicolas Gauthier
- Service d'Hématologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Maya Ouzegdouh
- Service d'Hématologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Marie Blonski
- Service de Neuro-Oncologie, Centre Hospitalier Régional Universitaire (CHRU), Université de Lorraine, Centre de Recherche en Automatique de Nancy CRAN UMR 7039, CNRS, Nancy, France
| | - Arnaud Campidelli
- Service d'Hématologie Clinique, Hôpital Brabois, Centre Hospitalier Régional Universitaire (CHRU), Nancy, CNRS UMR 7563, Biopôle de l'Université de Lorraine, Vandoeuvre les Nancy, France
| | - Guido Ahle
- Service de Neurologie, Hôpital Pasteur-Hôpitaux civils de Colmar, France
| | - Blandine Guffroy
- Service d'Hématologie Clinique, Institut de Cancérologie Strasbourg Europe, Strasbourg, France
| | - Lise Willems
- Service d'Hématologie Clinique, Hôpital Cochin, APHP, Paris, France
| | - Emilie Corvilain
- Service d'Immunologie Clinique, Hôpital Saint Louis, APHP, Université de Paris, Paris, France
| | - Maryline Barrie
- Service de Neuro-oncologie, Assistance Publique-Hôpitaux de Marseille (AP-HM), Hôpital de la Timone, Marseille, France
| | - Marion Alcantara
- Service d'Hématologie Clinique, Institut Curie, site de Saint Cloud, France and INSERM U932, Institut Curie, PSL Research University, Paris, France
| | - Magali le Garff-Tavernier
- Service d'Hématologie Biologique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Dimitri Psimaras
- Service de Neurooncologie, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, INSERM, CNRS, UMR S 1127, ICM, IHU, Paris, France
| | - Nicolas Weiss
- AP-HP, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, département de neurologie, unité de Médecine Intensive Réanimation à orientation neurologique, Paris, France
- Brain Liver Pitié-Salpêtrière (BLIPS) Study Group, INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
- Groupe de Recherche Clinique en REanimation et Soins intensifs du Patient en Insuffisance Respiratoire aiguE (GRC-RESPIRE), Sorbonne Université, Paris, France
| | - Marine Baron
- Service d'Hématologie Clinique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Clotilde Bravetti
- Service d'Hématologie Biologique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Khê Hoang-Xuan
- Service de Neurooncologie, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, INSERM, CNRS, UMR S 1127, ICM, IHU, Paris, France
| | - Frédéric Davi
- Service d'Hématologie Biologique, Groupe Hospitalier Pitié-Salpêtrière, APHP-Sorbonne Université, Paris, France
| | - Natalia Shor
- Service de Neuroradiologie, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
| | - Agusti Alentorn
- Service de Neurooncologie, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, INSERM, CNRS, UMR S 1127, ICM, IHU, Paris, France
| | - Caroline Houillier
- Service de Neurooncologie, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, INSERM, CNRS, UMR S 1127, ICM, IHU, Paris, France
| |
Collapse
|
4
|
Laribi K, Poulain S, Willems L, Merabet F, Herbaux C, Roos-Weil D, Laribi de Materre I, Roussel X, Nudel M, Tricot S, Dupuis J, Le Calloch R, Bareau B, Leblond V. Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO). Br J Haematol 2024. [PMID: 38504454 DOI: 10.1111/bjh.19409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2023] [Revised: 03/02/2024] [Accepted: 03/06/2024] [Indexed: 03/21/2024]
Abstract
The bendamustine-rituximab (BR) schedule is an efficient first-line therapy in Waldenström macroglobulinaemia (WM). A previous analysis of 69 patients who received this treatment confirmed a high response rate and good progression-free (PFS) and overall survival (OS). With a median follow-up of 76.1 months (95% confidence interval [CI] 69.9-80.6), 5-year outcome is still excellent at 66.63% (95% CI 56.09-79.17) for PFS and 80.01% (95% CI 70.82-90.41) for OS. The rate of secondary cancers is 17.66% (IQR 7.99-27.64) at 66 months. Relapsed patients who received ibrutinib as second-line clearly benefited from this schedule. This confirms current recommendations suggesting BR long-term efficacy as first-line option in WM.
Collapse
Affiliation(s)
- Kamel Laribi
- Haematology Department, Le Mans Hospital, Le Mans, France
| | - Stéphanie Poulain
- Cellular Haematology, Biology and Pathology Center, Lille Regional and University Hospital and INSERM UMR 1172, IRCL, Lille, France
| | - Lise Willems
- Haematology Clinic, Cochin Hospital, APHP, Paris, France
| | - Fatiha Merabet
- Haematology and Oncology Clinic, André Mignot Hospital, Versailles Hospital, Versailles, France
| | - Charles Herbaux
- Haematology Clinic, Montpellier University Hospital, Montpellier, France
| | - Damien Roos-Weil
- Haematology Department, APHP, Sorbonne University, University Hospital La Pitié Salpêtrière-Charles Foix, Paris, France
| | | | - Xavier Roussel
- Haematology Department, University of Franche-Comté, INSERM UMR 1098, Besançon University Hospital, Besançon, France
| | - Morgane Nudel
- Haematology Department, Lille Regional and University Hospital, Lille, France
| | - Sabine Tricot
- Haematology Clinic, Valenciennes Hospital, Valenciennes, France
| | - Jehan Dupuis
- Lymphoid Malignancies Unit, APHP, Henri Mondor-Albert Chennevier Hospital, Créteil, France
| | - Ronan Le Calloch
- Internal Medicine, Infectiology and Blood Diseases, Cornouaille Hospital Center, Quimper, France
| | - Benoit Bareau
- Haematology and Internal Medicine Clinic, Sévigné Vivalto Santé Private Hospital, Cesson-Sévigné, France
| | - Véronique Leblond
- Haematology Department, APHP, Sorbonne University, University Hospital La Pitié Salpêtrière-Charles Foix, Paris, France
| |
Collapse
|
5
|
Rozenblum L, Houillier C, Baptiste A, Soussain C, Edeline V, Naggara P, Soret M, Causse-Lemercier V, Willems L, Choquet S, Ursu R, Galanaud D, Belin L, Hoang-Xuan K, Kas A. Interim FDG-PET improves treatment failure prediction in primary central nervous system Lymphoma: a LOC network prospective multicentric study. Neuro Oncol 2024:noae029. [PMID: 38366824 DOI: 10.1093/neuonc/noae029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Indexed: 02/18/2024] Open
Abstract
PURPOSE The purpose of our study was to assess the predictive and prognostic role of 2-18F-fluoro-2-deoxy-D-glucose (FDG) PET/MRI during high-dose methotrexate-based chemotherapy (HD-MBC) in de novo primary central nervous system lymphoma (PCNSL) patients aged 60 and above. METHODS This prospective multicentric ancillary study included 65 immunocompetents patients who received induction HD-MBC as part of the BLOCAGE01 phase III trial. FDG-PET/MRI were acquired at baseline, post two cycles (PET/MRI2), and post-treatment (PET/MRI3). FDG-PET response was dichotomized, with "positive" indicating persistent tumor uptake higher than the contralateral mirroring brain region. Performances of FDG-PET and International PCNSL Collaborative Group criteria in predicting induction response, progression-free survival (PFS), and overall survival (OS) were compared. RESULTS Of 48 PET2 scans performed, nine were positive and aligned with a partial response (PR) on MRI2. Among these, eight (89%) progressed by the end of the induction phase. In contrast, 35/39 (90%) of PET2-negative patients achieved complete response (CR). Among the 18 discordant responses at interim (PETCR/MRIPR), 83% ultimately achieved CR. 87% of the PET2-negative patients were disease-free at 6 months versus 11% of the PET2-positive patients (p<0.001). The MRI2 response did not significantly differentiate patients based on their PFS, regardless of whether they were in CR or PR. Both PET2 and MRI2 independently predicted OS in multivariate analysis, with PET2 showing stronger association. CONCLUSION Our study highlights the potential of interim FDG-PET for early management of PCNSL patients. Response-driven treatment based on PET2 may guide future clinical trials.
Collapse
Affiliation(s)
- Laura Rozenblum
- Department of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
- Sorbonne Université, INSERM, CNRS, Laboratoire d'Imagerie Biomédicale, LIB, F-75006, Paris, France
| | - Caroline Houillier
- Department of Neurology 2 Mazarin, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, Paris, France
| | - Amandine Baptiste
- Department of Public Health, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Paris, France
| | - Carole Soussain
- Department of Haematology, Institut Curie, Site Saint-Cloud and INSERM U932 Institut Curie, Université PSL, 75005 Paris, France
| | | | - Philippe Naggara
- Department of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
| | - Marine Soret
- Department of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
- Sorbonne Université, INSERM, CNRS, Laboratoire d'Imagerie Biomédicale, LIB, F-75006, Paris, France
| | - Valérie Causse-Lemercier
- Department of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
| | - Lise Willems
- Department of Haematology, Cochin Hospital, APHP, Paris
| | - Sylvain Choquet
- Department of Haematology, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
| | - Renata Ursu
- Department of Neurology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, APHP, France
| | - Damien Galanaud
- Sorbonne Université, INSERM, CNRS, Laboratoire d'Imagerie Biomédicale, LIB, F-75006, Paris, France
- Department of Neuroradiology, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
| | - Lisa Belin
- Department of Public Health, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Paris, France
| | - Khê Hoang-Xuan
- Department of Neurology 2 Mazarin, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, Paris, France
| | - Aurélie Kas
- Department of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
- Sorbonne Université, INSERM, CNRS, Laboratoire d'Imagerie Biomédicale, LIB, F-75006, Paris, France
| |
Collapse
|
6
|
Kosmider O, Possémé C, Templé M, Corneau A, Carbone F, Duroyon E, Breillat P, Chirayath TW, Oules B, Sohier P, Luka M, Gobeaux C, Lazaro E, Outh R, Le Guenno G, Lifermann F, Berleur M, Le Mene M, Friedrich C, Lenormand C, Weitten T, Guillotin V, Burroni B, Boussier J, Willems L, Aractingi S, Dionet L, Tharaux PL, Vergier B, Raynaud P, Ea HK, Ménager M, Duffy D, Terrier B. VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation. Nat Commun 2024; 15:910. [PMID: 38291039 PMCID: PMC10828464 DOI: 10.1038/s41467-024-44811-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2022] [Accepted: 01/02/2024] [Indexed: 02/01/2024] Open
Abstract
Acquired mutations in the UBA1 gene were recently identified in patients with severe adult-onset auto-inflammatory syndrome called VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic). However, the precise physiological and clinical impact of these mutations remains poorly defined. Here we study a unique prospective cohort of VEXAS patients. We show that monocytes from VEXAS are quantitatively and qualitatively impaired and display features of exhaustion with aberrant expression of chemokine receptors. In peripheral blood from VEXAS patients, we identify an increase in circulating levels of many proinflammatory cytokines, including IL-1β and IL-18 which reflect inflammasome activation and markers of myeloid cells dysregulation. Gene expression analysis of whole blood confirms these findings and also reveals a significant enrichment of TNF-α and NFκB signaling pathways that can mediate cell death and inflammation. This study suggests that the control of the nflammasome activation and inflammatory cell death could be therapeutic targets in VEXAS syndrome.
Collapse
Affiliation(s)
- Olivier Kosmider
- Université de Paris Cité, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France.
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France.
| | - Céline Possémé
- Institut Pasteur, Université de Paris Cité, Translational Immunology Unit, Paris, France
| | - Marie Templé
- Université de Paris Cité, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France
| | - Aurélien Corneau
- Sorbonne Université, Faculté de Médecine, UMS037, PASS, Plateforme de Cytométrie de la Pitié-Salpêtrière CyPS, Paris, France
| | - Francesco Carbone
- Université de Paris Cité, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM UMR 1163, Paris, France
- Labtech Single-Cell@Imagine, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Eugénie Duroyon
- Université de Paris Cité, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France
| | - Paul Breillat
- Université de Paris Cité, INSERM, U970, PARCC, F-, Paris, France
- Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP, APHP-CUP, Hôpital Cochin, Paris, France
| | | | - Bénédicte Oules
- Department of Pathology, AP-HP, APHP-CUP, Hôpital Cochin, Paris, France
| | - Pierre Sohier
- Department of Pathology, AP-HP, APHP-CUP, Hôpital Cochin, Paris, France
| | - Marine Luka
- Université de Paris Cité, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM UMR 1163, Paris, France
- Labtech Single-Cell@Imagine, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Camille Gobeaux
- Biochemistry Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France
| | - Estibaliz Lazaro
- Department of Internal Medicine, Bordeaux University Hospital-Haut-Lévêque, Pessac, France
| | - Roderau Outh
- Department of Internal Medicine, Centre Hospitalier de Perpignan, Perpignan, France
| | - Guillaume Le Guenno
- Department of Internal Medicine, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | | | - Marie Berleur
- Department of Internal Medicine, AP-HP, APHP-NUP, Hôpital Bichat, Paris, France
| | - Melchior Le Mene
- Université de Paris Cité, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France
| | - Chloé Friedrich
- Université de Paris Cité, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France
| | - Cédric Lenormand
- Université de Strasbourg, Department of Dermatology, CHRU Strasbourg, Strasbourg, France
| | - Thierry Weitten
- Department of Internal Medicine, Centre Hospitalier (CHICAS), Gap, France
| | - Vivien Guillotin
- Department of Internal Medicine, Bordeaux University Hospital-Saint-André, Bordeaux, France
| | - Barbara Burroni
- Department of Pathology, AP-HP, APHP-CUP, Hôpital Cochin, Paris, France
| | - Jeremy Boussier
- Sorbonne University - 47-83 Boulevard de l'Hopital, Paris, France
| | - Lise Willems
- Université de Paris Cité, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France
- Hematology Department, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France
| | - Selim Aractingi
- Dermatology Department, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France
| | - Léa Dionet
- Université de Paris Cité, INSERM, U970, PARCC, F-, Paris, France
| | | | - Béatrice Vergier
- Pathology Department, Bordeaux University Hospital-Haut-Lévêque, Pessac, France
| | - Pierre Raynaud
- Pathology Department, Centre Hospitalier de Perpignan, Perpignan, France
| | - Hang-Korng Ea
- Université de Paris Cité, INSERM, UMR-S 1132 BIOSCAR, Paris, France
- Rheumatology Department, AP- HP, Lariboisière Hospital, Paris, France
| | - Mickael Ménager
- Université de Paris Cité, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM UMR 1163, Paris, France
- Labtech Single-Cell@Imagine, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Darragh Duffy
- Institut Pasteur, Université de Paris Cité, Translational Immunology Unit, Paris, France
| | - Benjamin Terrier
- Université de Paris Cité, INSERM, U970, PARCC, F-, Paris, France.
- Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP, APHP-CUP, Hôpital Cochin, Paris, France.
| |
Collapse
|
7
|
Ryngaert A, Gillet B, Burroni B, Willems L. Autoimmune myelofibrosis: clinical and histological efficacy of ciclosporin treatment. BMJ Case Rep 2024; 17:e256644. [PMID: 38272518 PMCID: PMC10826502 DOI: 10.1136/bcr-2023-256644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2024] Open
|
8
|
Loap P, El Ayachy R, Beddok A, Abbassi L, Boilève A, Deau Fischer B, Willems L, Franchi P, Bouscary D, Kirova Y. Evolution of radiotherapy techniques for mediastinal Hodgkin lymphoma: a single-center experience. Mediastinum 2023; 8:10. [PMID: 38322184 PMCID: PMC10839518 DOI: 10.21037/med-23-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Accepted: 11/20/2023] [Indexed: 02/08/2024]
Affiliation(s)
- Pierre Loap
- Department of Radiation Oncology, Institut Curie, Paris, France
| | | | - Arnaud Beddok
- Department of Radiation Oncology, Institut Curie, Paris, France
| | - Louisa Abbassi
- Department of Radiation Oncology, Institut Curie, Paris, France
| | - Alice Boilève
- Department of Radiation Oncology, Institut Curie, Paris, France
| | - Bénédicte Deau Fischer
- Department of Hematology, Assistance Publique-Hopitaux de Paris, Hopital Cochin, Paris, France
| | - Lise Willems
- Department of Hematology, Assistance Publique-Hopitaux de Paris, Hopital Cochin, Paris, France
| | - Patricia Franchi
- Department of Hematology, Assistance Publique-Hopitaux de Paris, Hopital Cochin, Paris, France
| | - Didier Bouscary
- Department of Hematology, Assistance Publique-Hopitaux de Paris, Hopital Cochin, Paris, France
| | - Youlia Kirova
- Department of Radiation Oncology, Institut Curie, Paris, France
| |
Collapse
|
9
|
Johnson N, Templé M, Friedrich C, Willems L, Birsen R, Vignon M, Deschamps P, Franchi P, Mondesir J, Deau-Fischer B, Miekoutima E, Boussaid I, Chapuis N, Kosmider O, Bouscary D, Tamburini J, Decroocq J. Subcutaneous azacitidine maintenance in transplantineligible patients with acute myeloid leukemia: a single-center retrospective study. Haematologica 2023; 108:2850-2854. [PMID: 36994502 PMCID: PMC10542839 DOI: 10.3324/haematol.2022.282009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Accepted: 03/23/2023] [Indexed: 03/31/2023] Open
Affiliation(s)
- Natacha Johnson
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris
| | - Marie Templé
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Cochin Hospital, Paris
| | - Chloe Friedrich
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Cochin Hospital, Paris, France; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, F-75014, Paris
| | - Lise Willems
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris
| | - Rudy Birsen
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris
| | - Marguerite Vignon
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris
| | - Paul Deschamps
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris
| | - Patricia Franchi
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris
| | - Johanna Mondesir
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris
| | - Benedicte Deau-Fischer
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris
| | - Elsa Miekoutima
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris
| | - Ismaël Boussaid
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Cochin Hospital, Paris
| | - Nicolas Chapuis
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Cochin Hospital, Paris, France; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, F-75014, Paris
| | - Olivier Kosmider
- Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Cochin Hospital, Paris, France; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, F-75014, Paris
| | - Didier Bouscary
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, F-75014, Paris
| | - Jerome Tamburini
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, F-75014, Paris, France; Translational Research Centre in Onco-hematology, Faculty of Medicine, University of Geneva, and Swiss Cancer Center Leman, Geneva, Switzerland
| | - Justine Decroocq
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris.
| |
Collapse
|
10
|
Rozenblum L, Galanaud D, Houillier C, Soussain C, Baptiste A, Belin L, Edeline V, Naggara P, Soret M, Causse-Lemercier V, Willems L, Choquet S, Ursu R, Hoang-Xuan K, Kas A. [18F]FDG PET-MRI provides survival biomarkers in primary central nervous system lymphoma in the elderly: an ancillary study from the BLOCAGE trial of the LOC network. Eur J Nucl Med Mol Imaging 2023; 50:3684-3696. [PMID: 37462774 DOI: 10.1007/s00259-023-06334-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2023] [Accepted: 07/05/2023] [Indexed: 10/04/2023]
Abstract
PURPOSE Primary central nervous system lymphoma (PCNSL) incidence is rising among elderly patients, presenting challenges due to poor prognosis and treatment-related toxicity risks. This study explores the potential of combining [18F]fluorodeoxyglucose ([18F]FDG) PET scans and multimodal MRI for improving management in elderly patients with de novo PCNSL. METHODS Immunocompetent patients over 60 years with de novo PCNSL were prospectively enrolled in a multicentric study between January 2016 and April 2021. Patients underwent brain [18F]FDG PET-MRI before receiving high-dose methotrexate-based chemotherapy. Relationships between extracted PET (metabolic tumor volume (MTV), sum of MTV for up to five lesions (sumMTV), metabolic imaging lymphoma aggressiveness score (MILAS)) and MRI parameters (tumor contrast-enhancement size, cerebral blood volume (CBV), cerebral blood flow (CBF), apparent diffusion coefficient (ADC)) and treatment response and outcomes were analyzed. RESULTS Of 54 newly diagnosed diffuse large B-cell PCNSL patients, 52 had positive PET and MRI with highly [18F]FDG-avid and contrast-enhanced disease (SUVmax: 27.7 [22.8-36]). High [18F]FDG uptake and metabolic volume were significantly associated with low ADCmean values and high CBF at baseline. Among patients, 69% achieved an objective response at the end of induction therapy, while 17 were progressive. Higher cerebellar SUVmean and lower sumMTV at diagnosis were significant predictors of complete response: 6.4 [5.7-7.7] vs 5.4 [4.5-6.6] (p = 0.04) and 5.5 [2.1-13.3] vs 15.9 [4.2-19.5] (p = 0.01), respectively. Two-year overall survival (OS) was 71%, with a median progression-free survival (PFS) of 29.6 months and a median follow-up of 37 months. Larger tumor volumes on PET or enhanced T1-weighted MRI were significant predictors of poorer OS, while a high MILAS score at diagnosis was associated with early death (< 1 year). CONCLUSION Baseline cerebellar metabolism and sumMTV may predict response to end of chemotherapy in PCNSL. Tumor volume and MILAS at baseline are strong prognostic factors.
Collapse
Affiliation(s)
- Laura Rozenblum
- Department of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France.
- Sorbonne Université, INSERM, CNRS, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France.
| | - Damien Galanaud
- Sorbonne Université, INSERM, CNRS, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France
- Department of Neuroradiology, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
| | - Caroline Houillier
- Deparrment of Neurology 2 Mazarin, APHP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, Paris, France
| | - Carole Soussain
- Department of Hematology, Institut Curie, Site Saint-Cloud and INSERM U932 Institut Curie, Université PSL, 75005, Paris, France
| | - Amandine Baptiste
- Department of Public Health, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie Et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Paris, France
| | - Lisa Belin
- Department of Public Health, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie Et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Paris, France
| | | | - Philippe Naggara
- Department of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
| | - Marine Soret
- Department of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
- Sorbonne Université, INSERM, CNRS, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France
| | - Valérie Causse-Lemercier
- Department of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
| | - Lise Willems
- Department of Hematology, Cochin Hospital, APHP, Paris, France
| | - Sylvain Choquet
- Department of Hematology, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
| | - Renata Ursu
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis, Service de Neurologie, Paris, France
| | - Khê Hoang-Xuan
- Deparrment of Neurology 2 Mazarin, APHP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, Paris, France
| | - Aurélie Kas
- Department of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
- Sorbonne Université, INSERM, CNRS, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France
| |
Collapse
|
11
|
Belhadj M, Burroni B, Kosmider O, Willems L, Temple M, Bertoli S, Orvain C, Dumas PY, Berthon C, Gabellier L, Marcais A, Raffoux E, Pautas C, Genthon A, Decroocq J, Birsen R, Tamburini J, Bouscary D, Contejean A. Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational study. Br J Haematol 2023; 202:e50-e53. [PMID: 37403204 DOI: 10.1111/bjh.18961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 06/19/2023] [Accepted: 06/21/2023] [Indexed: 07/06/2023]
Affiliation(s)
- Maya Belhadj
- Faculté de Médecine Sorbonne Paris Cité, Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Université Paris Descartes, Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Hôpital Necker, Paris, France
| | - Barbara Burroni
- Department of Pathology, Centre de Recherche des Cordeliers UMRS U1138, GH Paris Centre APHP, Université de Paris Cité, Paris, France
| | - Olivier Kosmider
- Faculté de Médecine Sorbonne Paris Cité, Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Université Paris Descartes, Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Biologique, Hôpital Cochin, Paris, France
| | - Lise Willems
- Faculté de Médecine Sorbonne Paris Cité, Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Université Paris Descartes, Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
- The Organization for Partnerships in Leukemia, OPALE Carnot Institute, Paris, France
| | - Marie Temple
- Faculté de Médecine Sorbonne Paris Cité, Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Université Paris Descartes, Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Biologique, Hôpital Cochin, Paris, France
| | - Sarah Bertoli
- Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Corentin Orvain
- Service Maladies du Sang, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - Pierre-Yves Dumas
- Cellules Souches Hématopoïétiques Normales et Leucémiques, INSERM U1312 BRIC, Université de Bordeaux, Bordeaux, France
- CHU Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, Bordeaux, France
| | - Celine Berthon
- Service Maladies du Sang, Centre Hospitalier Universitaire de Lille, Lille, France
- UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, Lille, France
| | - Ludovic Gabellier
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - Ambroise Marcais
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Hôpital Necker, Paris, France
| | - Emmanuel Raffoux
- Service d'Hématologie Adultes, Hôpital Saint-Louis, Groupe hospitalo-universitaire AP-HP, Paris, France
| | - Cecile Pautas
- Service d'Hématologie Clinique, Hôpital Henri Mondor, Groupe hospitalo-universitaire AP-HP, Créteil, France
| | - Alexis Genthon
- Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint-Antoine, Groupe hospitalo-universitaire AP-HP, Paris, France
| | - Justine Decroocq
- Faculté de Médecine Sorbonne Paris Cité, Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Université Paris Descartes, Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
| | - Rudy Birsen
- Faculté de Médecine Sorbonne Paris Cité, Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Université Paris Descartes, Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
- The Organization for Partnerships in Leukemia, OPALE Carnot Institute, Paris, France
| | - Jerome Tamburini
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
- Translational Research Centre in Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Swiss Cancer Center Leman, Geneva, Switzerland
| | - Didier Bouscary
- Faculté de Médecine Sorbonne Paris Cité, Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Université Paris Descartes, Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
- The Organization for Partnerships in Leukemia, OPALE Carnot Institute, Paris, France
| | - Adrien Contejean
- Faculté de Médecine Sorbonne Paris Cité, Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Université Paris Descartes, Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
- Service d'Hématologie Clinique, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France
| |
Collapse
|
12
|
Detroit M, Collier M, Beeker N, Willems L, Decroocq J, Deau-Fischer B, Vignon M, Birsen R, Moufle F, Leclaire C, Balladur E, Deschamps P, Chauchet A, Batista R, Limat S, Treluyer JM, Ricard L, Stocker N, Hermine O, Choquet S, Morel V, Metz C, Bouscary D, Kroemer M, Zerbit J. Predictive Factors of Response to Immunotherapy in Lymphomas: A Multicentre Clinical Data Warehouse Study (PRONOSTIM). Cancers (Basel) 2023; 15:4028. [PMID: 37627056 PMCID: PMC10452259 DOI: 10.3390/cancers15164028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Revised: 08/04/2023] [Accepted: 08/07/2023] [Indexed: 08/27/2023] Open
Abstract
Immunotherapy (IT) is a major therapeutic strategy for lymphoma, significantly improving patient prognosis. IT remains ineffective for a significant number of patients, however, and exposes them to specific toxicities. The identification predictive factors around efficacy and toxicity would allow better targeting of patients with a higher ratio of benefit to risk. PRONOSTIM is a multicenter and retrospective study using the Clinical Data Warehouse (CDW) of the Greater Paris University Hospitals network. Adult patients with Hodgkin lymphoma or diffuse large-cell B lymphoma treated with immune checkpoint inhibitors or CAR T (Chimeric antigen receptor T) cells between 2017 and 2022 were included. Analysis of covariates influencing progression-free survival (PFS) or the occurrence of grade ≥3 toxicity was performed. In total, 249 patients were included. From this study, already known predictors for response or toxicity of CAR T cells such as age, elevated lactate dehydrogenase, and elevated C-Reactive Protein at the time of infusion were confirmed. In addition, male gender, low hemoglobin, and hypo- or hyperkalemia were demonstrated to be potential predictive factors for progression after CAR T cell therapy. These findings prove the attractiveness of CDW in generating real-world data, and show its essential contribution to identifying new predictors for decision support before starting IT.
Collapse
Affiliation(s)
- Marion Detroit
- Pharmacy Department, Pitié-Salpêtrière Hospital, Greater Paris University Hospitals (AP-HP), Sorbonne University, 75013 Paris, France; (M.D.); (C.M.)
| | - Mathis Collier
- Clinical Research Unit, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France; (M.C.); (N.B.); (J.-M.T.)
| | - Nathanaël Beeker
- Clinical Research Unit, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France; (M.C.); (N.B.); (J.-M.T.)
| | - Lise Willems
- Hematology Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France; (L.W.); (J.D.); (B.D.-F.); (M.V.); (R.B.); (D.B.)
| | - Justine Decroocq
- Hematology Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France; (L.W.); (J.D.); (B.D.-F.); (M.V.); (R.B.); (D.B.)
| | - Bénédicte Deau-Fischer
- Hematology Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France; (L.W.); (J.D.); (B.D.-F.); (M.V.); (R.B.); (D.B.)
| | - Marguerite Vignon
- Hematology Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France; (L.W.); (J.D.); (B.D.-F.); (M.V.); (R.B.); (D.B.)
| | - Rudy Birsen
- Hematology Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France; (L.W.); (J.D.); (B.D.-F.); (M.V.); (R.B.); (D.B.)
| | - Frederique Moufle
- Adult Department, Hospital at Home, AP-HP, Centre Paris-Cité University, 75014 Paris, France; (F.M.); (C.L.); (E.B.)
| | - Clément Leclaire
- Adult Department, Hospital at Home, AP-HP, Centre Paris-Cité University, 75014 Paris, France; (F.M.); (C.L.); (E.B.)
| | - Elisabeth Balladur
- Adult Department, Hospital at Home, AP-HP, Centre Paris-Cité University, 75014 Paris, France; (F.M.); (C.L.); (E.B.)
| | - Paul Deschamps
- Hematology Oncology Department, André Mignot Hospital, 78157 Le Chesnay, France;
| | - Adrien Chauchet
- Hematology Department, University Hospital of Besançon, 25000 Besançon, France;
| | - Rui Batista
- Pharmacy Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France;
| | - Samuel Limat
- Pharmacy Department, University Hospital of Besançon, 25000 Besançon, France; (S.L.); (M.K.)
- French National Institute of Health and Medical Research (INSERM), Etablissement Français du Sang Bourgogne Franche-Comte (EFS BFC), UMR1098, RIGHT, University of Bourgogne Franche-Comté, 25000 Besançon, France
| | - Jean-Marc Treluyer
- Clinical Research Unit, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France; (M.C.); (N.B.); (J.-M.T.)
- Regional Pharmacovigilance Center, Pharmacology Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France
| | - Laure Ricard
- Hematology Department, Saint Antoine Hospital, AP-HP, INSERM UMRs 938, Sorbonne University, 75012 Paris, France; (L.R.); (N.S.)
| | - Nicolas Stocker
- Hematology Department, Saint Antoine Hospital, AP-HP, INSERM UMRs 938, Sorbonne University, 75012 Paris, France; (L.R.); (N.S.)
| | - Olivier Hermine
- Hematology Department, Necker Hospital, AP-HP, Centre Paris-Cité University, 75015 Paris, France;
| | - Sylvain Choquet
- Hematology Department, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, 75013 Paris, France; (S.C.); (V.M.)
| | - Véronique Morel
- Hematology Department, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, 75013 Paris, France; (S.C.); (V.M.)
| | - Carole Metz
- Pharmacy Department, Pitié-Salpêtrière Hospital, Greater Paris University Hospitals (AP-HP), Sorbonne University, 75013 Paris, France; (M.D.); (C.M.)
| | - Didier Bouscary
- Hematology Department, Cochin Hospital, AP-HP, Centre Paris-Cité University, 75014 Paris, France; (L.W.); (J.D.); (B.D.-F.); (M.V.); (R.B.); (D.B.)
| | - Marie Kroemer
- Pharmacy Department, University Hospital of Besançon, 25000 Besançon, France; (S.L.); (M.K.)
- French National Institute of Health and Medical Research (INSERM), Etablissement Français du Sang Bourgogne Franche-Comte (EFS BFC), UMR1098, RIGHT, University of Bourgogne Franche-Comté, 25000 Besançon, France
| | - Jérémie Zerbit
- Cancer Treatment Unit, Pharmacy Department, Hospital at Home, AP-HP, Centre Paris-Cité University, 75014 Paris, France
| |
Collapse
|
13
|
Breal C, Beuvon F, de Witasse-Thezy T, Dermine S, Franchi-Rezgui P, Deau-Fisher B, Willems L, Grignano E, Contejean A, Bouscary D, Faillie JL, Treluyer JM, Guerin C, Chouchana L, Vignon M. Management of Gastro-Intestinal Toxicity of the Pi3 Kinase Inhibitor: Optimizing Future Dosing Strategies. Cancers (Basel) 2023; 15:cancers15082279. [PMID: 37190206 DOI: 10.3390/cancers15082279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Revised: 04/06/2023] [Accepted: 04/09/2023] [Indexed: 05/17/2023] Open
Abstract
The phosphatidylinositol 3-kinase (PI3K) pathway plays a key role in cancer progression and in host immunity. Idelalisib was the first of this class to be approved with the second-generation Pi3 kinase inhibitors copanlisib, duvelisib and umbralisib, subsequently being approved in the United States. Real-world data are lacking, however, in relation to the incidence and toxicity of Pi3 kinase inhibitor-induced colitis. We here review, in the first instance, the general landscape of the Pi3K inhibitors in the context of hematological malignancies, with a focus on the adverse gastrointestinal side effects reported by various clinical trials. We further review the available worldwide pharmacovigilance data in relation to these drugs. Finally, we describe our own real-world experience with idelalisib-induced colitis management in our center and in a national setting.
Collapse
Affiliation(s)
- Claire Breal
- Service d'Hématologie Clinique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, 75014 Paris, France
| | - Frederic Beuvon
- Anatomopathologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, 75014 Paris, France
| | - Thibault de Witasse-Thezy
- Centre Régional de Pharmacovigilance, Service de Pharmacologie, Hôpital Cochin, AP-HP, Centre-Université de Paris, 75014 Paris, France
| | - Solene Dermine
- Gastro-Entérologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, 75014 Paris, France
| | - Patricia Franchi-Rezgui
- Service d'Hématologie Clinique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, 75014 Paris, France
| | - Benedicte Deau-Fisher
- Service d'Hématologie Clinique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, 75014 Paris, France
| | - Lise Willems
- Service d'Hématologie Clinique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, 75014 Paris, France
| | - Eric Grignano
- Service d'Hématologie Clinique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, 75014 Paris, France
| | - Adrien Contejean
- Service d'Hématologie Clinique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, 75014 Paris, France
| | - Didier Bouscary
- Service d'Hématologie Clinique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, 75014 Paris, France
| | - Jean Luc Faillie
- Centre Régional de Pharmacovigilance, CHU Montpellier, IDESP, INSERM, University of Montpellier, 34193 Montpellier, France
| | - Jean-Marc Treluyer
- Centre Régional de Pharmacovigilance, Service de Pharmacologie, Hôpital Cochin, AP-HP, Centre-Université de Paris, 75014 Paris, France
| | - Corinne Guerin
- Pharmacie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, 75014 Paris, France
| | - Laurent Chouchana
- Centre Régional de Pharmacovigilance, Service de Pharmacologie, Hôpital Cochin, AP-HP, Centre-Université de Paris, 75014 Paris, France
| | - Marguerite Vignon
- Service d'Hématologie Clinique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, 75014 Paris, France
| |
Collapse
|
14
|
Sutra Del Galy A, Willems L, D'Aveni M, Pautas C, Chantepie S, Carpentier B, Barraco F, Banos A, Garidi R, Forcade E, Sicre de Fontbrune F, Peffault de Latour R. Haemolytic paroxysmal nocturnal haemoglobinuria in patients with myeloid neoplasms: A rare association with specific therapeutic implications. Br J Haematol 2023; 201:e16-e20. [PMID: 36807116 DOI: 10.1111/bjh.18693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Revised: 01/11/2023] [Accepted: 01/30/2023] [Indexed: 02/20/2023]
Affiliation(s)
| | - Lise Willems
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire Cochin, Paris, France
| | - Maud D'Aveni
- Service d'Hématologie, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France
| | - Cécile Pautas
- Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Henri Mondor, Créteil, France
| | | | | | - Fiorenza Barraco
- Service d'Hématologie, Centre Hospitalier Universitaire Lyon Sud, Lyon, France
| | - Anne Banos
- Service d'Hématologie, Centre Hospitalier de la Côte Basque, Bayonne, France
| | - Reda Garidi
- Service d'Onco-Hématologie, Centre Hospitalier de Saint Quentin, Saint-Quentin, France
| | - Edouard Forcade
- Service d'Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France
| | | | | |
Collapse
|
15
|
Guillet S, Loustau V, Boutin E, Zarour A, Comont T, Souchaud-Debouverie O, Costedoat Chalumeau N, Pan-Petesch B, Gobert D, Cheze S, Viallard JF, Morin AS, Sauvetre G, Cliquennois M, Royer B, Masseau A, Terriou L, Fieschi C, Lambotte O, Girault S, Lioger B, Audia S, Sacre K, Lega JC, Langlois V, Benachi A, Orvain C, Devidas A, Humbert S, Gambier N, Ruivard M, Zarrouk V, Ebbo M, Willems L, Segaux L, Mahevas M, Haddad B, Michel M, Canoui-Poitrine F, Godeau B. Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study. Blood 2023; 141:11-21. [PMID: 36054922 PMCID: PMC10644036 DOI: 10.1182/blood.2022017277] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 07/18/2022] [Accepted: 08/03/2022] [Indexed: 01/10/2023] Open
Abstract
The risk of immune thrombocytopenia (ITP) worsening during pregnancy and neonatal ITP (NITP) have never been prospectively studied. We included 180 pregnant and 168 nonpregnant women with ITP in a prospective, multicenter, observational cohort study. A total of 131 pregnant women with ITP were matched to 131 nonpregnant women with ITP by history of splenectomy, ITP status (no response, response, complete response), and duration. Groups were followed for 15 months. The primary outcome was the first occurrence of ITP worsening defined by a composite end point including bleeding events and/or severe thrombocytopenia (<30 × 109/L) and/or ITP treatment modification. We also studied the recurrence of ITP worsening and the incidence of NITP and risk factors. The first occurrence of ITP worsening did not differ between pregnant and nonpregnant women with ITP (53.4 per 100 person-years [95% confidence interval {CI}, 40.8-69.9] vs 37.1 [95% CI, 27.5-50.0]; hazard ratio {HR}, 1.35 [95% CI, 0.89-2.03], P = .16). Pregnant women with ITP were more likely to have recurrence of severe thrombocytopenia and treatment modification (HR, 2.71 [95% CI, 1.41-5.23], P = .003; HR, 2.01 [95% CI, 1.14-3.57], P = .017, respectively). However, recurrence of severe bleeding events was not different between groups (P = .4). Nineteen (14%) neonates showed NITP <50 × 109/L. By multivariable analysis, NITP was associated with a previous offspring with NITP and maternal platelet count <50 × 109/L within 3 months before delivery (adjusted odds ratio, 5.55 [95% CI, 1.72-17.89], P = .004 and 4.07 [95% CI, 1.41-11.73], P = .009). To conclude, women with ITP do not increase their risk of severe bleeding during pregnancy. NITP is associated with NITP history and the severity of maternal ITP during pregnancy. These results will be useful for counseling women with ITP.
Collapse
MESH Headings
- Infant, Newborn
- Female
- Humans
- Pregnancy
- Purpura, Thrombocytopenic, Idiopathic/epidemiology
- Purpura, Thrombocytopenic, Idiopathic/therapy
- Purpura, Thrombocytopenic, Idiopathic/complications
- Cohort Studies
- Prospective Studies
- Pregnancy Complications, Hematologic/epidemiology
- Pregnancy Complications, Hematologic/therapy
- Thrombocytopenia, Neonatal Alloimmune/therapy
- Retrospective Studies
Collapse
Affiliation(s)
- Stéphanie Guillet
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
| | - Valentine Loustau
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
- Service de Médecine Interne, Centre Hospitalier Alpes Léman, Contamine sur Arve, France
| | - Emmanuelle Boutin
- Unité de Recherche Clinique (URC Mondor), AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
- Univ Paris Est Créteil, INSERM, IMRB, Equipe CEpiA (Clinical Epidemiology and Ageing), Créteil, France
| | - Anissa Zarour
- Unité de Recherche Clinique (URC Mondor), AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - Thibault Comont
- Service de Médecine Interne et d’Immunopathologie–IUCT-Oncopole, CHU de Toulouse, Toulouse, France
| | | | - Nathalie Costedoat Chalumeau
- Service de Médecine Interne, Centre de Référence Maladies Auto-immunes et Systémiques Rares, Hôpital Cochin, AP-HP, Université de Paris, Paris, France
- Centre for Clinical Epidemiology, Hôpital Hôtel-Dieu, AP-HP, Université de Paris, Centre of Research in Epidemiology and Statistics, Paris, France
| | | | - Delphine Gobert
- Service de Médecine Interne, Hôpital Saint Antoine, AP-HP, Sorbonne Université, Paris, France
| | - Stéphane Cheze
- Institut d’Hématologie de Basse-Normandie, Centre Hospitalier de Caen Normandie, Caen, France
| | | | - Anne-Sophie Morin
- Service de Médecine Interne, Hôpital Jean Verdier, AP-HP, Bondy, France
| | - Gaetan Sauvetre
- Service de Médecine Interne, Hôpital Charles Nicolle, Université de Rouen, Rouen, France
| | - Manuel Cliquennois
- Service d'Onco-hématologie Adulte, Hôpital Saint-Vincent de Paul, GH de l'institut Catholique de Lille, Lille, France
| | - Bruno Royer
- Service d’Immuno-hématologie, Hôpital Saint Louis, Paris, France
- Service d’Hématologie clinique, CHU d’Amiens, Amiens, France
| | - Agathe Masseau
- Service de Médecine Interne, CHU de Nantes, Nantes, France
| | - Louis Terriou
- Service de Médecine Interne et d’Immunologie Clinique, CHU Lille, Université de Lille, Lille, France
| | - Claire Fieschi
- Service d’Immunologie Clinique, Hôpital Saint Louis, AP-HP, Paris, France
| | - Olivier Lambotte
- Service de Médecine Interne et d’Immunologie Clinique, Hôpital Bicêtre, Université Paris Sacly, Le Kremlin-Bicêtre, France
| | - Stéphane Girault
- Service d’Hématologie Clinique et de Thérapie Cellulaire, CHU Dupuytren, Limoges, France
| | | | - Sylvain Audia
- Service de Médecine Interne et d’Immunologie Clinique, Centre de Référence Constitutif des Cytopénies Auto-Immunes, Hôpital François Mitterrand, CHU Dijon-Bourgogne, Dijon, France
| | - Karim Sacre
- Service de Médecine Interne, Hôpital Bichat, AP-HP, Paris, France et Université de Paris, Centre de Recherche sur l’Inflammation, INSERM UMR1149, CNRS ERL8252, Laboratoire d’Excellence Inflamex, Paris, France
| | - Jean Christophe Lega
- Service de Médecine Interne et Médecine Vasculaire, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, Université de Lyon, Lyon, France
- Laboratoire de Biométrie et Biologie Évolutive, CNRS-UMR 5588, Université Lyon 1, Lyon, France
| | - Vincent Langlois
- Service de Médecine Interne, Hôpital Jacques Monod, Le Havre, France
| | - Alexandra Benachi
- Service d’Obstétrique et Gynécologie, Hôpital Antoine-Béclère, AP-HP, Université Paris-Saclay, Clamart, France
| | - Corentin Orvain
- Service d’Hématologie, Hôpital d’Anger, INSERM, CRCINA, Université d’Angers, Angers, France
| | - Alain Devidas
- Service d’Hématologie Clinique, CH Sud Francilien, Corbeil Essonnes, France
| | | | - Nicolas Gambier
- Service de Médecine Interne, CH Général Delafontaine, St Denis, France
| | - Marc Ruivard
- Service de Médecine Interne, CHU Estaing, Clermont-Ferrand, France
| | - Virginie Zarrouk
- Service de Médecine Interne, Hôpital Beaujon, AP-HP, Clichy, France
| | - Mikael Ebbo
- Service de Médecine Interne, Hôpital de la Conception, AP-HP, Université Aix-Marseille, Marseille, France
| | - Lise Willems
- Service d’Hématologie Clinique, Hôpital Cochin, Paris, France
| | - Lauriane Segaux
- Service de Santé Publique, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - Matthieu Mahevas
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
| | - Bassam Haddad
- Centre Hospitalier Inter-Communal de Créteil, Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Equipe Immunorégulation et Biothérapie (I-BIOT), Université Paris Est Créteil, Univ Paris Est Créteil, INSERM U955, Institut Mondor De Recherche Biomédicale (IMRB), Créteil, France
| | - Marc Michel
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
| | - Florence Canoui-Poitrine
- Unité de Recherche Clinique (URC Mondor), AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
- Service de Santé Publique, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - Bertrand Godeau
- Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l’adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France
| |
Collapse
|
16
|
Zerbit J, Kroemer M, Fuchs B, Detroit M, Decroocq J, Vignon M, Willems L, Deau‐Fischer B, Franchi P, Deschamps P, Contejean A, Grignano E, Fouquet G, Birsen R, Mondesir J, Rocquet M, Huon J, Batista R, Marty‐Reboul J, Bouscary D. Pharmaceutical cancer care for haematology patients on oral anticancer drugs: Findings from an economic, clinical and organisational analysis. Eur J Cancer Care (Engl) 2022; 31:e13753. [DOI: 10.1111/ecc.13753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 09/26/2022] [Accepted: 10/09/2022] [Indexed: 11/28/2022]
Affiliation(s)
- Jeremie Zerbit
- Pharmacy Department, Hospital at Home University Hospitals of Paris (AP‐HP) Paris France
| | - Marie Kroemer
- Pharmacy Department University Hospital of Besançon Besançon France
| | - Basile Fuchs
- Medical Information, Cochin Hospital University Hospitals of Paris (AP‐HP) Paris France
| | - Marion Detroit
- Pharmacy Department University Hospital of Besançon Besançon France
| | - Justine Decroocq
- Clinical Hematology, Cochin Hospital University Hospitals of Paris (AP‐HP) Paris France
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016 Paris France
- Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC) Paris France
| | - Marguerite Vignon
- Clinical Hematology, Cochin Hospital University Hospitals of Paris (AP‐HP) Paris France
| | - Lise Willems
- Clinical Hematology, Cochin Hospital University Hospitals of Paris (AP‐HP) Paris France
| | | | - Patricia Franchi
- Clinical Hematology, Cochin Hospital University Hospitals of Paris (AP‐HP) Paris France
| | - Paul Deschamps
- Clinical Hematology, Cochin Hospital University Hospitals of Paris (AP‐HP) Paris France
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016 Paris France
- Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC) Paris France
| | | | - Eric Grignano
- Clinical Hematology, Cochin Hospital University Hospitals of Paris (AP‐HP) Paris France
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016 Paris France
- Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC) Paris France
| | - Guillemette Fouquet
- Hematology Department Centre Hospitalier Sud Francilien Corbeil‐Essonnes France
| | - Rudy Birsen
- Clinical Hematology, Cochin Hospital University Hospitals of Paris (AP‐HP) Paris France
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016 Paris France
- Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC) Paris France
| | - Johanna Mondesir
- Clinical Hematology, Cochin Hospital University Hospitals of Paris (AP‐HP) Paris France
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016 Paris France
- Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC) Paris France
| | - Mathieu Rocquet
- Hematology Department Necker Hospital, University Hospitals of Paris (AP‐HP) Paris France
| | - Jean‐François Huon
- INSERM, UMR 1246‐SPHERE, MethodS in Patients‐Centered Outcomes and HEalth ResEarch Nantes France
- Clinical Pharmacy Unit Nantes University Hospital Nantes France
| | - Rui Batista
- Clinical Pharmacy, Cochin Hospital University Hospitals of Paris (AP‐HP) Paris France
| | - Jeanne Marty‐Reboul
- Medical Information, Cochin Hospital University Hospitals of Paris (AP‐HP) Paris France
| | - Didier Bouscary
- Clinical Hematology, Cochin Hospital University Hospitals of Paris (AP‐HP) Paris France
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016 Paris France
- Équipe Labellisée Ligue Nationale Contre le Cancer (LNCC) Paris France
| |
Collapse
|
17
|
Jachiet V, Ricard L, Hirsch P, Malard F, Pascal L, Beyne-Rauzy O, Peterlin P, Maria ATJ, Vey N, D'Aveni M, Gourin MP, Dimicoli-Salazar S, Banos A, Wickenhauser S, Terriou L, De Renzis B, Durot E, Natarajan-Ame S, Vekhoff A, Voillat L, Park S, Vinit J, Dieval C, Dellal A, Grobost V, Willems L, Rossignol J, Solary E, Kosmider O, Dulphy N, Zhao LP, Adès L, Fenaux P, Fain O, Mohty M, Gaugler B, Mekinian A. Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases. Clin Exp Med 2022:10.1007/s10238-022-00866-5. [PMID: 35953763 DOI: 10.1007/s10238-022-00866-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 07/13/2022] [Indexed: 11/28/2022]
Abstract
BACKGROUND Systemic inflammatory and autoimmune diseases (SIADs) occur in 10-20% of patients with myelodysplastic syndrome (MDS). Recently identified VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, associated with somatic mutations in UBA1 (Ubiquitin-like modifier-activating enzyme 1), encompasses a range of severe inflammatory conditions along with hematological abnormalities, including MDS. The pathophysiological mechanisms underlying the association between MDS and SIADs remain largely unknown, especially the roles of different myeloid immune cell subsets. The aim of this study was to quantitatively evaluate peripheral blood myeloid immune cells (dendritic cells (DC) and monocytes) by flow cytometry in MDS patients with associated SIAD (n = 14, most often including relapsing polychondritis or neutrophilic dermatoses) and to compare their distribution in MDS patients without SIAD (n = 23) and healthy controls (n = 7). Most MDS and MDS/SIAD patients had low-risk MDS. Eight of 14 (57%) MDS/SIAD patients carried UBA1 somatic mutations, defining VEXAS syndrome.Compared with MDS patients, most DC and monocyte subsets were significantly decreased in MDS/SIAD patients, especially in MDS patients with VEXAS syndrome. Our study provides the first overview of the peripheral blood immune myeloid cell distribution in MDS patients with associated SIADs and raises several hypotheses: possible redistribution to inflammation sites, increased apoptosis, or impaired development in the bone marrow.
Collapse
Affiliation(s)
- Vincent Jachiet
- Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), 75012, Paris, France. .,Service de Médecine Interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France.
| | - Laure Ricard
- Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), 75012, Paris, France.,Service d'Hématologie Clinique et de Thérapie Cellulaire, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France
| | - Pierre Hirsch
- Service d'Hématologie Biologique, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France
| | - Florent Malard
- Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), 75012, Paris, France.,Service d'Hématologie Clinique et de Thérapie Cellulaire, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France
| | - Laurent Pascal
- Service d'Oncologie et d'Hématologie, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France
| | - Odile Beyne-Rauzy
- Service de Médecine Interne, CHU de Toulouse, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
| | - Pierre Peterlin
- Service d'Hématologie Clinique, CHU de Nantes, Nantes, France
| | - Alexandre Thibault Jacques Maria
- Service de Médecine Interne, maladies multi-organiques de l'adulte, Hôpital Saint-Éloi, CHU de Montpellier, Université de Montpellier, Montpellier, France
| | - Norbert Vey
- Institut Paoli-Calmettes, CRCM, Aix-Marseille Univ, Inserm, CNRS, Marseille, France
| | - Maud D'Aveni
- Service d'Hématologie et de Médecine Interne, Hôpital Brabois, CHRU Nancy, Nancy, France
| | - Marie-Pierre Gourin
- Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Dupuytren, CHU de Limoges, Limoges, France
| | | | - Anne Banos
- Service d'Hématologie Clinique, Centre Hospitalier Côte Basque, Bayonne, France
| | - Stefan Wickenhauser
- Service d'Hématologie Clinique, Hôpital Universitaire Carémeau, Institut de Cancérologie du Gard, Nîmes, France
| | - Louis Terriou
- Service de Médecine Interne et Immunologie Clinique, CHU Lille, 59000, Lille, France
| | - Benoit De Renzis
- Service d'Hématologie Clinique, Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France
| | - Eric Durot
- Service d'Hématologie Clinique, Hôpital Robert Debré, CHU de Reims, Reims, France
| | - Shanti Natarajan-Ame
- Service d'Hématologie, Institut de Cancérologie Strasbourg Europe (ICANS), 17 rue Albert Calmette, Strasbourg, France
| | - Anne Vekhoff
- Service d'Hématologie Clinique et de Thérapie Cellulaire, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France
| | - Laurent Voillat
- Service d'Hématologie et Oncologie, CH William Morey, Chalon sur Saône, France
| | - Sophie Park
- Service d'Hématologie, Université Grenoble Alpes Et CHU Grenoble Alpes, Grenoble, France
| | - Julien Vinit
- Service de Médecine Interne, CH William Morey, Chalon sur Saône, France
| | - Céline Dieval
- Service de Médecine Interne et Hématologie, GHLA, CH de Rochefort, Rochefort, France
| | - Azeddine Dellal
- Service de Rhumatologie, Hôpital Montfermeil, Montfermeil, France
| | - Vincent Grobost
- Service de Médecine Interne, CHU Estaing, Clermont-Ferrand, France
| | - Lise Willems
- Service d'Hématologie, AP-HP, Hôpital Cochin, Paris, France
| | - Julien Rossignol
- Service d'Hématologie Adultes, AP-HP, Hôpital Necker-Enfants Malades, 75015, Paris, France
| | - Eric Solary
- Département d'Hématologie, Institut Gustave Roussy, Villejuif, France
| | - Olivier Kosmider
- Service d'Hématologie Biologique, Université de Paris, AP-HP, Hôpital Cochin, 75014, Paris, France
| | - Nicolas Dulphy
- Institut de Recherche Saint Louis, Hôpital Saint Louis, Université de Paris, INSERM U1160, Paris, France
| | - Lin Pierre Zhao
- Département d'Hématologie, Université de Paris, AP-HP, Hôpital Saint Louis, 75010, Paris, France
| | - Lionel Adès
- Département d'Hématologie, Université de Paris, AP-HP, Hôpital Saint Louis, 75010, Paris, France
| | - Pierre Fenaux
- Département d'Hématologie, Université de Paris, AP-HP, Hôpital Saint Louis, 75010, Paris, France
| | - Olivier Fain
- Service de Médecine Interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France
| | - Mohamad Mohty
- Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), 75012, Paris, France.,Service d'Hématologie Clinique et de Thérapie Cellulaire, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France
| | - Béatrice Gaugler
- Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), 75012, Paris, France.,Service d'Hématologie Clinique et de Thérapie Cellulaire, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France
| | - Arsène Mekinian
- Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), 75012, Paris, France.,Service de Médecine Interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France
| | | |
Collapse
|
18
|
Contejean A, Abbara S, Chentouh R, Alviset S, Grignano E, Gastli N, Casetta A, Willems L, Canouï E, Charlier C, Pène F, Charpentier J, Reboul-Marty J, Batista R, Bouscary D, Kernéis S. Antimicrobial stewardship in high-risk febrile neutropenia patients. Antimicrob Resist Infect Control 2022; 11:52. [PMID: 35346373 PMCID: PMC8961889 DOI: 10.1186/s13756-022-01084-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Accepted: 02/20/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The 2011 4th European Conference on Infections in Leukemia (ECIL4) guidelines recommend antibiotics de-escalation/discontinuation in selected febrile neutropenia (FN) patients. We aimed to assess the impact of an antimicrobial stewardship (AMS) program based on these guidelines on antibiotics use and clinical outcomes in high-risk FN patients. METHODS We conducted an observational study in the hematology department of Cochin University Hospital in Paris, France. An ECIL4-based antibiotics de-escalation and discontinuation strategy was implemented jointly by the hematologists and the AMS team. The pre-intervention (January-October 2018) and post-intervention (January-October 2019) periods were compared. We retrospectively collected clinical and microbiological data. We compiled antibiotics consumptions via hospital pharmacy data and standardized them by calculating defined daily doses per 1000 patient-days. We analyzed the two-monthly antibiotic consumption using an interrupted time series method and built a composite endpoint for clinical outcomes based on transfer to the intensive care unit (ICU) and/or hospital death. RESULTS Overall, 273 hospital stays (164 patients) in the pre-intervention and 217 (148 patients) in the post-intervention periods were analyzed. Patients were mainly hospitalized for intensive chemotherapy for acute leukemia or autologous stem-cell transplant for myeloma. Patients were slightly younger in the pre-intervention compared to the post-intervention period (median age 60.4 vs 65.2 years, p = 0.049), but otherwise comparable. After implementation of the AMS program, glycopeptide and carbapenem use decreased by 85% (p = 0.03) and 72% (p = 0.04), respectively. After adjustment on confounders, the risk of transfer to the ICU/death decreased significantly after implementation of the AMS program (post-intervention period: odds-ratio = 0.29, 95% Confidence Interval: 0.15-0.53, p < 0.001). CONCLUSION Implementation of a multidisciplinary AMS program for high-risk neutropenic patients was associated with lower carbapenem and glycopeptide use and improved clinical outcomes.
Collapse
Affiliation(s)
- Adrien Contejean
- Faculté de Médecine, Université de Paris, 75006, Paris, France. .,Service d'hématologie, AP-HP, APHP.CUP, Hôpital Cochin, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France. .,Équipe Mobile d'Infectiologie, AP-HP, APHP.CUP, Hôpital Cochin, 75014, Paris, France.
| | - Salam Abbara
- UVSQ, Inserm, CESP, Anti-infective Evasion and Pharmacoepidemiology Team, Université Paris-Saclay, 78180, Montigny-le-Bretonneux, France.,Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), 75015, Paris, France
| | - Ryme Chentouh
- Équipe Mobile d'Infectiologie, AP-HP, APHP.CUP, Hôpital Cochin, 75014, Paris, France
| | - Sophie Alviset
- Équipe Mobile d'Infectiologie, AP-HP, APHP.CUP, Hôpital Cochin, 75014, Paris, France
| | - Eric Grignano
- Service d'hématologie, AP-HP, APHP.CUP, Hôpital Cochin, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France
| | - Nabil Gastli
- Laboratoire de bactériologie, AP-HP, APHP.CUP, Hôpital Cochin, 75014, Paris, France
| | - Anne Casetta
- Equipe opérationnelle d'hygiène hospitalière, AP-HP, Hôpital Cochin, 75014, Paris, France
| | - Lise Willems
- Service d'hématologie, AP-HP, APHP.CUP, Hôpital Cochin, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France
| | - Etienne Canouï
- Équipe Mobile d'Infectiologie, AP-HP, APHP.CUP, Hôpital Cochin, 75014, Paris, France
| | - Caroline Charlier
- Faculté de Médecine, Université de Paris, 75006, Paris, France.,Équipe Mobile d'Infectiologie, AP-HP, APHP.CUP, Hôpital Cochin, 75014, Paris, France.,Institut Pasteur, Biology of Infection Unit, INSERM U1117, French National Reference Center and WHO Collaborating Center Listeria, Paris, France
| | - Frédéric Pène
- Faculté de Médecine, Université de Paris, 75006, Paris, France.,Service de médecine intensive réanimation, AP-HP, APHP.CUP, Hôpital Cochin, 75014, Paris, France
| | - Julien Charpentier
- Service de médecine intensive réanimation, AP-HP, APHP.CUP, Hôpital Cochin, 75014, Paris, France
| | - Jeanne Reboul-Marty
- Département d'information médicale, AP-HP, APHP.CUP, Hôpital Cochin, 75014, Paris, France
| | - Rui Batista
- Pharmacie hospitalière, AP-HP, APHP.CUP, Hôpital Cochin, 75014, Paris, France
| | - Didier Bouscary
- Faculté de Médecine, Université de Paris, 75006, Paris, France.,Service d'hématologie, AP-HP, APHP.CUP, Hôpital Cochin, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France
| | - Solen Kernéis
- Équipe Mobile d'Infectiologie, AP-HP, APHP.CUP, Hôpital Cochin, 75014, Paris, France.,Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), 75015, Paris, France.,INSERM, IAME, Université de Paris, 75006, Paris, France
| |
Collapse
|
19
|
Houillier C, Chabrot CM, Moles-Moreau MP, Willems L, Ahle G, Waultier-Rascalou A, Fornecker LM, Hoang-Xuan K, Soussain C. Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network. Neurology 2021; 97:628-631. [PMID: 34580183 DOI: 10.1212/wnl.0000000000012515] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Accepted: 06/30/2021] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND AND OBJECTIVES To evaluate the efficacy and tolerance of the association rituximab-lenalidomide-ibrutinib (R2I) in relapsed/refractory (R/R) primary CNS lymphoma (PCNSL). METHODS R/R PCNSL patients treated with R2I were retrospectively selected and analyzed from the French LOC database. RESULTS Fourteen patients (median age: 63 years, median Karnofsky Performance Status: 75%) received R2I, administered after a median of 2 previous lines of chemotherapy, including autologous stem cell transplantation (ASCT) in 5 cases. The best response was complete response in 4/14 patients and partial response in 4/14 patients, achieved in a median of 2.5 months. Three responder patients received consolidation treatment (WBRT: N = 2, ASCT: N = 1) after R2I, and R2I served as a bridge before CAR-T cell therapy for one patient. R2I was discontinued due to toxicity in 3/14 patients. There were no toxicity-related deaths. DISCUSSION The R2I combination resulted in a high rate of response of rapid-onset in heavily pretreated patients with poor prognosis, with manageable toxicity, and allowed 3 patients to proceed to consolidation. Although preliminary, these results support the use of R2I for R/R PCNSL failing conventional chemotherapies. CLASSIFICATION OF EVIDENCE This study provides Class IV evidence that combination of rituximab-lenalidomide-ibrutinib induces a high rate of response in heavily pretreated R/R PCNSL.
Collapse
Affiliation(s)
- Caroline Houillier
- From the APHP (C.H., K.H.-X.), Sorbonne Université, IHU, ICM, Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris; Service d'Hématologie (C.M.C.), CHU de Clermont-Ferrand, Clermont-Ferrand; Service des Maladies du Sang (M.-P.M.-M.), CHU d'Angers; APHP (L.W.), Hôpital Cochin, Service d'Hématologie, Paris; Service de Neurologie (G.A.), Hôpitaux Civils, Colmar; Service d'Hématologie (A.W.-R.), CHU de Nîmes; Service d'Hématologie (L.-M.F.), Institut de Cancérologie de Strasbourg Europe, Strasbourg; Service d'Hématologie (C.S.), Institut Curie, Site Saint Cloud; INSERM U932 (C.S.), Institut Curie, PSL Research University, Paris.
| | - Cecile Moluçon Chabrot
- From the APHP (C.H., K.H.-X.), Sorbonne Université, IHU, ICM, Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris; Service d'Hématologie (C.M.C.), CHU de Clermont-Ferrand, Clermont-Ferrand; Service des Maladies du Sang (M.-P.M.-M.), CHU d'Angers; APHP (L.W.), Hôpital Cochin, Service d'Hématologie, Paris; Service de Neurologie (G.A.), Hôpitaux Civils, Colmar; Service d'Hématologie (A.W.-R.), CHU de Nîmes; Service d'Hématologie (L.-M.F.), Institut de Cancérologie de Strasbourg Europe, Strasbourg; Service d'Hématologie (C.S.), Institut Curie, Site Saint Cloud; INSERM U932 (C.S.), Institut Curie, PSL Research University, Paris
| | - Marie-Pierre Moles-Moreau
- From the APHP (C.H., K.H.-X.), Sorbonne Université, IHU, ICM, Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris; Service d'Hématologie (C.M.C.), CHU de Clermont-Ferrand, Clermont-Ferrand; Service des Maladies du Sang (M.-P.M.-M.), CHU d'Angers; APHP (L.W.), Hôpital Cochin, Service d'Hématologie, Paris; Service de Neurologie (G.A.), Hôpitaux Civils, Colmar; Service d'Hématologie (A.W.-R.), CHU de Nîmes; Service d'Hématologie (L.-M.F.), Institut de Cancérologie de Strasbourg Europe, Strasbourg; Service d'Hématologie (C.S.), Institut Curie, Site Saint Cloud; INSERM U932 (C.S.), Institut Curie, PSL Research University, Paris
| | - Lise Willems
- From the APHP (C.H., K.H.-X.), Sorbonne Université, IHU, ICM, Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris; Service d'Hématologie (C.M.C.), CHU de Clermont-Ferrand, Clermont-Ferrand; Service des Maladies du Sang (M.-P.M.-M.), CHU d'Angers; APHP (L.W.), Hôpital Cochin, Service d'Hématologie, Paris; Service de Neurologie (G.A.), Hôpitaux Civils, Colmar; Service d'Hématologie (A.W.-R.), CHU de Nîmes; Service d'Hématologie (L.-M.F.), Institut de Cancérologie de Strasbourg Europe, Strasbourg; Service d'Hématologie (C.S.), Institut Curie, Site Saint Cloud; INSERM U932 (C.S.), Institut Curie, PSL Research University, Paris
| | - Guido Ahle
- From the APHP (C.H., K.H.-X.), Sorbonne Université, IHU, ICM, Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris; Service d'Hématologie (C.M.C.), CHU de Clermont-Ferrand, Clermont-Ferrand; Service des Maladies du Sang (M.-P.M.-M.), CHU d'Angers; APHP (L.W.), Hôpital Cochin, Service d'Hématologie, Paris; Service de Neurologie (G.A.), Hôpitaux Civils, Colmar; Service d'Hématologie (A.W.-R.), CHU de Nîmes; Service d'Hématologie (L.-M.F.), Institut de Cancérologie de Strasbourg Europe, Strasbourg; Service d'Hématologie (C.S.), Institut Curie, Site Saint Cloud; INSERM U932 (C.S.), Institut Curie, PSL Research University, Paris
| | - Agathe Waultier-Rascalou
- From the APHP (C.H., K.H.-X.), Sorbonne Université, IHU, ICM, Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris; Service d'Hématologie (C.M.C.), CHU de Clermont-Ferrand, Clermont-Ferrand; Service des Maladies du Sang (M.-P.M.-M.), CHU d'Angers; APHP (L.W.), Hôpital Cochin, Service d'Hématologie, Paris; Service de Neurologie (G.A.), Hôpitaux Civils, Colmar; Service d'Hématologie (A.W.-R.), CHU de Nîmes; Service d'Hématologie (L.-M.F.), Institut de Cancérologie de Strasbourg Europe, Strasbourg; Service d'Hématologie (C.S.), Institut Curie, Site Saint Cloud; INSERM U932 (C.S.), Institut Curie, PSL Research University, Paris
| | - Luc-Matthieu Fornecker
- From the APHP (C.H., K.H.-X.), Sorbonne Université, IHU, ICM, Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris; Service d'Hématologie (C.M.C.), CHU de Clermont-Ferrand, Clermont-Ferrand; Service des Maladies du Sang (M.-P.M.-M.), CHU d'Angers; APHP (L.W.), Hôpital Cochin, Service d'Hématologie, Paris; Service de Neurologie (G.A.), Hôpitaux Civils, Colmar; Service d'Hématologie (A.W.-R.), CHU de Nîmes; Service d'Hématologie (L.-M.F.), Institut de Cancérologie de Strasbourg Europe, Strasbourg; Service d'Hématologie (C.S.), Institut Curie, Site Saint Cloud; INSERM U932 (C.S.), Institut Curie, PSL Research University, Paris
| | - Khê Hoang-Xuan
- From the APHP (C.H., K.H.-X.), Sorbonne Université, IHU, ICM, Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris; Service d'Hématologie (C.M.C.), CHU de Clermont-Ferrand, Clermont-Ferrand; Service des Maladies du Sang (M.-P.M.-M.), CHU d'Angers; APHP (L.W.), Hôpital Cochin, Service d'Hématologie, Paris; Service de Neurologie (G.A.), Hôpitaux Civils, Colmar; Service d'Hématologie (A.W.-R.), CHU de Nîmes; Service d'Hématologie (L.-M.F.), Institut de Cancérologie de Strasbourg Europe, Strasbourg; Service d'Hématologie (C.S.), Institut Curie, Site Saint Cloud; INSERM U932 (C.S.), Institut Curie, PSL Research University, Paris
| | - Carole Soussain
- From the APHP (C.H., K.H.-X.), Sorbonne Université, IHU, ICM, Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris; Service d'Hématologie (C.M.C.), CHU de Clermont-Ferrand, Clermont-Ferrand; Service des Maladies du Sang (M.-P.M.-M.), CHU d'Angers; APHP (L.W.), Hôpital Cochin, Service d'Hématologie, Paris; Service de Neurologie (G.A.), Hôpitaux Civils, Colmar; Service d'Hématologie (A.W.-R.), CHU de Nîmes; Service d'Hématologie (L.-M.F.), Institut de Cancérologie de Strasbourg Europe, Strasbourg; Service d'Hématologie (C.S.), Institut Curie, Site Saint Cloud; INSERM U932 (C.S.), Institut Curie, PSL Research University, Paris
| |
Collapse
|
20
|
Lazarian G, Munger M, Quinquenel A, Dilhuydy M, Veronese L, Luque Paz D, Guièze R, Ledoux‐Pilon A, Paillassa J, Merabet F, Vial J, Bidet A, Waultier Rascalou A, Broseus J, Roos‐Weil D, Lavaud A, Molina L, Laribi K, Hivert B, Friedrich C, Carpentier B, Ysebaert L, Van Den Neste E, Willems L, Corby A, Poulain S, Eclache V, Maubec E, Martin A, Feugier P, Delmer A, Baran‐Marszak F, Leprêtre S, Cymbalista F. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO). Am J Hematol 2021; 96:E353-E356. [PMID: 34152612 DOI: 10.1002/ajh.26274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Accepted: 06/12/2021] [Indexed: 11/09/2022]
Affiliation(s)
- Grégory Lazarian
- Laboratoire d'hématologie Hôpital Avicenne ‐ INSERM U978‐ Université Paris Sorbonne Nord Bobigny France
| | - Michaël Munger
- Hématologie CHU de Québec ‐ Hôpital de l'Enfant‐Jésus Québec City Québec Canada
| | - Anne Quinquenel
- Service d'hématologie CHU de Reims, Hôpital Robert‐Debré, Université Reims Champagne‐Ardenne Reims France
| | - Marie‐Sarah Dilhuydy
- Service d'hématologie clinique et thérapie cellulaire CHU Bordeaux – Groupe Sud (Hôpital Haut‐Lévèque) Bordeaux France
| | - Lauren Veronese
- Cytogénétique Médicale Hématologie‐Oncologie, CHU Estaing Clermont‐Ferrand France
| | | | - Romain Guièze
- Service de thérapie cellulaire et hématologie clinique CHU de Clermont Ferrand Clermont‐Ferrand France
| | | | | | - Fatiha Merabet
- Service d'hématologie Hôpital de Versailles, Université Versailles Saint Quentin France
| | - Jean‐Philippe Vial
- Laboratoire d'hématologie CHU Bordeaux – Groupe Sud (Hôpital Haut‐Lévèque) Bordeaux France
| | - Audrey Bidet
- Laboratoire d'hématologie CHU Bordeaux – Groupe Sud (Hôpital Haut‐Lévèque) Bordeaux France
| | | | - Julien Broseus
- Laboratoire d'hématologie CHRU de Nancy Vandoeuvre‐lès‐Nancy France
| | - Damien Roos‐Weil
- Sorbonne Université, Service d'hématologie clinique, GH Pitie‐ Salpêtrière Paris France
| | - Anne Lavaud
- Sorbonne Université, Service d'hématologie clinique, GH Pitie‐ Salpêtrière Paris France
| | | | | | - Bénédicte Hivert
- Hématologie clinique Groupement des Hôpitaux de l'Institut Catholique de Lille Hôpital St Vincent de Paul Lille France
| | | | | | - Loïc Ysebaert
- Hématologie clinique Institut Universitaire du Cancer de Toulouse (IUCT) – Oncopole Toulouse France
| | | | - Lise Willems
- Hématologie clinique Hôpital Cochin Paris France
| | - Anne Corby
- Service d'oncologie hématologie Groupe hospitalier la Rochelle Hématologie Adulte La Rochelle France
| | - Stéphanie Poulain
- Hematology Laboratory, Biology and Pathology Center CHU de Lille Lille France
| | - Virginie Eclache
- Laboratoire d'hématologie Hôpital Avicenne ‐ INSERM U978‐ Université Paris Sorbonne Nord Bobigny France
| | - Eve Maubec
- Service de Dermatologie Hôpital Avicenne Bobigny France
| | - Antoine Martin
- Laboratoire d'anatomocytopathologie Hôpital Avicenne Bobigny France
| | - Pierre Feugier
- Département d'hématologie CHRU de Nancy Vandoeuvre‐lès‐Nancy France
| | - Alain Delmer
- Service d'hématologie CHU de Reims, Hôpital Robert‐Debré, Université Reims Champagne‐Ardenne Reims France
| | - Fanny Baran‐Marszak
- Laboratoire d'hématologie Hôpital Avicenne ‐ INSERM U978‐ Université Paris Sorbonne Nord Bobigny France
| | - Stéphane Leprêtre
- Département d'Hématologie Centre Henri Becquerel, Normandie université UNIROUEN Rouen France
| | - Florence Cymbalista
- Laboratoire d'hématologie Hôpital Avicenne ‐ INSERM U978‐ Université Paris Sorbonne Nord Bobigny France
| |
Collapse
|
21
|
Fouquet G, Wartski M, Dechmi A, Willems L, Deau-Fischer B, Franchi P, Descroocq J, Deschamps P, Blanc-Autran E, Clerc J, Bouscary D, Barreau S, Chapuis N, Vignon M, Cottereau AS. Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy. Cancers (Basel) 2021; 13:4323. [PMID: 34503133 PMCID: PMC8431719 DOI: 10.3390/cancers13174323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 08/25/2021] [Accepted: 08/25/2021] [Indexed: 11/16/2022] Open
Abstract
Although anti-CD38 monoclonal antibodies have improved the prognosis of relapsed/refractory multiple myeloma (RRMM), some patients still experience early relapses with poor outcomes. This present study evaluated the predictive value of FDG PET/CT parameters for RRMM prior to initiating anti-CD38 treatment. We included 38 consecutive RRMM patients who underwent a PET/CT scan treated at our institution at relapse. The median PFS was 12.5 months and the median OS was not reached. 42% of the patients had an initial ISS score of 1, 37% of 2, and 21% of 3. The presence of >3 focal lesions (FLs, n = 19) and the ISS score were associated with inferior PFS (p = 0.0036 and p = 0.0026) and OS (p = 0.025 and p = 0.0098). Patients with >3 FLs had a higher initial ISS score (p = 0.028). In multivariable analysis, the ISS score and >3 FLs were independent prognostic factors for PFS (p = 0.010 and p = 0.025 respectively), and combined they individualized a high-risk group with a median PFS and OS of 3.1 months and 8.5 months respectively vs. not reached for the other patients. The presence of >3 FLs on PET was predictive of survival outcomes in patients with RRMM treated using CD38 targeted therapy. Combined with the initial ISS, an ultra-high-risk RRMM population can thus be identified.
Collapse
Affiliation(s)
- Guillemette Fouquet
- Assistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d’Hématologie Clinique, Hôpital Cochin, 75014 Paris, France; (G.F.); (L.W.); (B.D.-F.); (P.F.); (J.D.); (P.D.); (D.B.); (M.V.)
| | - Myriam Wartski
- Assistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service de Médecine Nucléaire, Hôpital Cochin, 75014 Paris, France; (M.W.); (A.D.); (J.C.)
| | - Amina Dechmi
- Assistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service de Médecine Nucléaire, Hôpital Cochin, 75014 Paris, France; (M.W.); (A.D.); (J.C.)
| | - Lise Willems
- Assistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d’Hématologie Clinique, Hôpital Cochin, 75014 Paris, France; (G.F.); (L.W.); (B.D.-F.); (P.F.); (J.D.); (P.D.); (D.B.); (M.V.)
| | - Bénédicte Deau-Fischer
- Assistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d’Hématologie Clinique, Hôpital Cochin, 75014 Paris, France; (G.F.); (L.W.); (B.D.-F.); (P.F.); (J.D.); (P.D.); (D.B.); (M.V.)
| | - Patricia Franchi
- Assistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d’Hématologie Clinique, Hôpital Cochin, 75014 Paris, France; (G.F.); (L.W.); (B.D.-F.); (P.F.); (J.D.); (P.D.); (D.B.); (M.V.)
| | - Justine Descroocq
- Assistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d’Hématologie Clinique, Hôpital Cochin, 75014 Paris, France; (G.F.); (L.W.); (B.D.-F.); (P.F.); (J.D.); (P.D.); (D.B.); (M.V.)
| | - Paul Deschamps
- Assistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d’Hématologie Clinique, Hôpital Cochin, 75014 Paris, France; (G.F.); (L.W.); (B.D.-F.); (P.F.); (J.D.); (P.D.); (D.B.); (M.V.)
| | - Estelle Blanc-Autran
- Hôpital Marie Lannelongue, Service de Médecine Nucléaire, 92350 Le Plessis-Robinson, France;
| | - Jérôme Clerc
- Assistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service de Médecine Nucléaire, Hôpital Cochin, 75014 Paris, France; (M.W.); (A.D.); (J.C.)
| | - Didier Bouscary
- Assistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d’Hématologie Clinique, Hôpital Cochin, 75014 Paris, France; (G.F.); (L.W.); (B.D.-F.); (P.F.); (J.D.); (P.D.); (D.B.); (M.V.)
| | - Sylvain Barreau
- Assistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service D’hémato-Biologie, Hôpital Cochin, 75014 Paris, France; (S.B.); (N.C.)
| | - Nicolas Chapuis
- Assistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service D’hémato-Biologie, Hôpital Cochin, 75014 Paris, France; (S.B.); (N.C.)
| | - Marguerite Vignon
- Assistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service d’Hématologie Clinique, Hôpital Cochin, 75014 Paris, France; (G.F.); (L.W.); (B.D.-F.); (P.F.); (J.D.); (P.D.); (D.B.); (M.V.)
| | - Anne-Ségolène Cottereau
- Assistance Publique-Hôpitaux de Paris Centre, Université de Paris, Service de Médecine Nucléaire, Hôpital Cochin, 75014 Paris, France; (M.W.); (A.D.); (J.C.)
| |
Collapse
|
22
|
Zerbit J, Tamburini J, Goldwirt L, Decroocq J, Cayuela JM, Chapuis N, Contejean A, Batista R, Bouscary D, Willems L. Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma 2021; 62:3558-3560. [PMID: 34405773 DOI: 10.1080/10428194.2021.1966787] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Jérémie Zerbit
- Pharmacy Department, Assistance Publique-Hopitaux de Paris, Université de Paris, Paris, France
| | - Jerome Tamburini
- Hematology Department, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Université de Paris, Paris, France
| | - Lauriane Goldwirt
- Pharmacology Department, Saint-Louis Hospital, Assistance Publique-Hopitaux de Paris, Université de Paris, Paris, France
| | - Justine Decroocq
- Pharmacology Department, Saint-Louis Hospital, Assistance Publique-Hopitaux de Paris, Université de Paris, Paris, France
| | - Jean Michel Cayuela
- Laboratory of Hematology, Saint-Louis Hospital, Assistance Publique-Hopitaux de Paris, Université de Paris, University Paris Diderot, Paris, France
| | - Nicolas Chapuis
- Laboratory of Hematology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Université de Paris, Paris, France
| | - Adrien Contejean
- Hematology Department, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Université de Paris, Paris, France
| | - Rui Batista
- Pharmacy Department, Assistance Publique-Hopitaux de Paris, Université de Paris, Paris, France
| | - Didier Bouscary
- Pharmacology Department, Saint-Louis Hospital, Assistance Publique-Hopitaux de Paris, Université de Paris, Paris, France
| | - Lise Willems
- Pharmacology Department, Saint-Louis Hospital, Assistance Publique-Hopitaux de Paris, Université de Paris, Paris, France
| |
Collapse
|
23
|
Houillier C, Moluçon‐Chabrot C, Moles M, Willems L, Ahle G, Waultier A, Fornecker L, Hoang‐Xuan K, Soussain C. COMBINATION OF RITUXIMAB‐LENALIDOMIDE‐IBRUTINIB IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA: A COHORT STUDY OF THE LOC NETWORK. Hematol Oncol 2021. [DOI: 10.1002/hon.73_2880] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- C Houillier
- Hôpital Pitié‐Salpêtrière Neuro‐oncology Paris France
| | | | | | | | - G. Ahle
- Hospices Civils Neurology Colmar France
| | | | - L.‐M. Fornecker
- Institut de Cancérologie de Strasbourg Europe Hematology Strasbourg France
| | - K. Hoang‐Xuan
- Hôpital Pitié‐Salpêtrière Neuro‐oncology Paris France
| | - C. Soussain
- Institut Curie Hematology Saint Cloud France
| |
Collapse
|
24
|
Alcantara M, Houillier C, Garff‐Tavernier M, Souchet L, Roos‐Weil D, Morel V, Uzunov M, Metz C, Nguyen‐Quoc S, Jacque N, Gauthier N, Cann M, Norol F, Willems L, Waultier Rascalou A, Salanoubat C, Fior R, Blonski M, Rubio M, Soussain C, Choquet S. CAR‐T CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL): THE EXPERIENCE OF THE FRENCH NETWORK FOR OCULO‐CEREBRAL LYMPHOMAS (LOC). Hematol Oncol 2021. [DOI: 10.1002/hon.74_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
| | - C. Houillier
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | | | - L. Souchet
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - D. Roos‐Weil
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - V. Morel
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - M. Uzunov
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - C. Metz
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - S. Nguyen‐Quoc
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - N. Jacque
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - N. Gauthier
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - M. Cann
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | - F. Norol
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| | | | | | - C. Salanoubat
- Centre Hospitalier Sud Francilien 91106 Corbeil Essonnes France
| | - R. Fior
- Hôpital Antoine‐Béclère 92140 Clamart France
| | - M. Blonski
- Centre Hospitalier Régional et Universitaire de Nancy 54035 Nancy France
| | - M.‐T. Rubio
- Centre Hospitalier Régional et Universitaire de Nancy 54035 Nancy France
| | | | - S. Choquet
- Hôpital Universitaire Pitié‐Salpêtrière 75013 Paris France
| |
Collapse
|
25
|
Briantais A, Séguier J, De Sainte Marie B, Mekinian A, Belizna C, Gondran G, Maurier F, Trouiller S, Willems L, Beyne-Rauzy O, Harlé JR, Vey N, Ebbo M, Schleinitz N. Inflammatory myopathies associated with myelodysplastic syndromes: A French multicenter case control study and literature review. Semin Arthritis Rheum 2021; 51:845-852. [PMID: 34175790 DOI: 10.1016/j.semarthrit.2021.05.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Revised: 04/06/2021] [Accepted: 05/31/2021] [Indexed: 12/17/2022]
Abstract
OBJECTIVE Patients with inflammatory myopathies (IM) are known to have an increased risk of developing malignancies. Autoimmune and inflammatory diseases occur in up to 25% of patients with myelodysplastic syndrome (MDS). This study aimed to describe the rare association between IM and MDS. METHODS We report here the main characteristics, treatment, and outcome of 21 patients (11 national cases and 10 additional cases from a literature review) with IM associated to MDS. RESULTS Median age of patients at IM diagnosis was 66 years (range 26 - 78). Diagnosis of the two conditions were concomitant in most patients (n=14/21) whereas MDS diagnosis preceded IM diagnosis in 5 patients. Different types of IM were observed but dermatomyositis was the most frequent (59%). Compared to IM without MDS (IM/MDS-), patients with MDS (IM/MDS+) were older (median 66 vs 55, p=0.3), more frequently male (sex ratio M/F 1.125 vs 0.41, p=0.14) and positive for anti-TIF1γ (24% vs 4%, p=0.0039). Antisynthetase syndrome was never observed among IM/MDS+ patients (0% vs 28%, p=0.01). MDS WHO type was not univocal, but the prognostic score was of low risk in almost all cases. IM was usually steroid sensitive (82% of patients) but often steroid dependent (56% of patients). Overall survival of IM patients with MDS was worse compared to patients with IM without MDS (p=0.0002). CONCLUSION IM associated with MDS are mainly represented by dermatomyositis and/or anti-TIF1γ autoantibodies. Antisynthetase syndrome has not been described in association with MDS. Despite low-risk MDS, overall survival of IM patients with MDS is worse than IM patients without MDS.
Collapse
Affiliation(s)
- Antoine Briantais
- Aix Marseille Univ, Department of Internal Medicine, Assistance Publique - Hôpitaux de Marseille, CHU La Timone, Marseille, France.
| | - Julie Séguier
- Aix Marseille Univ, Department of Internal Medicine, Assistance Publique - Hôpitaux de Marseille, CHU La Timone, Marseille, France
| | - Benjamin De Sainte Marie
- Aix Marseille Univ, Department of Internal Medicine, Assistance Publique - Hôpitaux de Marseille, CHU La Timone, Marseille, France
| | - Arsène Mekinian
- Sorbonne Université, Department of Internal Medicine, Assistance Publique - Hôpitaux de Paris, CHU Saint-Antoine, Paris, France
| | | | | | - François Maurier
- Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France
| | - Sébastien Trouiller
- Departement of Internal Medicine, Centre Hospitalier d'Aurillac, Aurillac, France
| | - Lise Willems
- Department of hematology, Assistance Publique - Hôpitaux de Paris, CHU Cochin, Paris, France
| | - Odile Beyne-Rauzy
- Department of Internal Medicine, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Jean-Robert Harlé
- Aix Marseille Univ, Department of Internal Medicine, Assistance Publique - Hôpitaux de Marseille, CHU La Timone, Marseille, France
| | - Norbert Vey
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - Mikael Ebbo
- Aix Marseille Univ, Department of Internal Medicine, Assistance Publique - Hôpitaux de Marseille, CHU La Timone, Marseille, France
| | - Nicolas Schleinitz
- Aix Marseille Univ, Department of Internal Medicine, Assistance Publique - Hôpitaux de Marseille, CHU La Timone, Marseille, France
| |
Collapse
|
26
|
Fouquet G, Wartski M, Dechmi A, Willems L, Deau‐Fischer B, Franchi P, Descroocq J, Deschamps P, Clerc J, Bouscary D, Barreau S, Chapuis N, Vignon M, Cottereau A. PREDICTIVE VALUE OF FDG PET/CT IN PATIENTS WITH RELAPSE/REFRACTORY MULTIPLE MYELOMA BEFORE TREATMENT WITH ANTI‐CD38 IMMUNOTHERAPY. Hematol Oncol 2021. [DOI: 10.1002/hon.99_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- G. Fouquet
- Cochin Hospital APHP, Paris, France Hematology Paris France
| | - M. Wartski
- Cochin Hospital APHP, Paris Nuclear Medicine Paris France
| | - A. Dechmi
- Cochin Hospital APHP, Paris Nuclear Medicine Paris France
| | - L. Willems
- Cochin Hospital APHP, Paris, France Hematology Paris France
| | | | - P. Franchi
- Cochin Hospital APHP, Paris, France Hematology Paris France
| | - J. Descroocq
- Cochin Hospital APHP, Paris, France Hematology Paris France
| | - P. Deschamps
- Cochin Hospital APHP, Paris, France Hematology Paris France
| | - J. Clerc
- Cochin Hospital APHP, Paris Nuclear Medicine Paris France
| | - D. Bouscary
- Cochin Hospital APHP, Paris, France Hematology Paris France
| | - S. Barreau
- Hôpital Cochin APHP Service d'hématologie biologique Paris France
| | - N. Chapuis
- Hôpital Cochin APHP Service d'hématologie biologique Paris France
| | - M. Vignon
- Cochin Hospital APHP, Paris, France Hematology Paris France
| | | |
Collapse
|
27
|
Loubiere M, Brasme H, Docteur PR, Roubeau V, Maisonobe T, Vignon M, Willems L, Zuber M. Neuropathie amyloïde AL révélée par une plexopathie unilatérale. Rev Neurol (Paris) 2021. [DOI: 10.1016/j.neurol.2021.02.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Vazquez R, Breal C, Zalmai L, Friedrich C, Almire C, Contejean A, Barreau S, Grignano E, Willems L, Deau-Fischer B, Franchi P, Vignon M, Decroocq J, Birsen R, Goldwirt L, Kaltenbach S, Couronne L, Fontenay M, Kosmider O, Bouscary D, Chapuis N. Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis. Blood Cancer J 2021; 11:62. [PMID: 33741892 PMCID: PMC7979724 DOI: 10.1038/s41408-021-00448-w] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Revised: 02/18/2021] [Accepted: 02/19/2021] [Indexed: 12/12/2022] Open
Affiliation(s)
- Romain Vazquez
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Biologique, Hôpital Cochin, Paris, France
| | - Claire Breal
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
| | - Loria Zalmai
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Biologique, Hôpital Cochin, Paris, France
| | - Chloe Friedrich
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Biologique, Hôpital Cochin, Paris, France.,Université de Paris, Institut Cochin, CNRSUMR8104, INSERM U1016, A Member of OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France
| | - Carole Almire
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Biologique, Hôpital Cochin, Paris, France
| | - Adrien Contejean
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
| | - Sylvain Barreau
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Biologique, Hôpital Cochin, Paris, France.,Université de Paris, Institut Cochin, CNRSUMR8104, INSERM U1016, A Member of OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France
| | - Eric Grignano
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France.,Université de Paris, Institut Cochin, CNRSUMR8104, INSERM U1016, A Member of OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France
| | - Lise Willems
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France.,Université de Paris, Institut Cochin, CNRSUMR8104, INSERM U1016, A Member of OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France
| | - Benedicte Deau-Fischer
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
| | - Patricia Franchi
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
| | - Marguerite Vignon
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
| | - Justine Decroocq
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
| | - Rudy Birsen
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
| | - Lauriane Goldwirt
- Assistance Publique-Hôpitaux de Paris, Nord-Université de Paris, Laboratoire de Pharmacologie Biologique, UMRS976, Hôpital Saint Louis, Paris, France
| | - Sophie Kaltenbach
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Laboratoire d'Onco-Hématologie, Hôpital Necker-Enfants maladies, Paris, France.,Université de Paris, Institut Necker-Enfants Malades, INSERM U1151, Paris, France
| | - Lucile Couronne
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Laboratoire d'Onco-Hématologie, Hôpital Necker-Enfants maladies, Paris, France.,Université de Paris, Institut Imagine, INSERM U1163, Paris, France
| | - Michaela Fontenay
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Biologique, Hôpital Cochin, Paris, France.,Université de Paris, Institut Cochin, CNRSUMR8104, INSERM U1016, A Member of OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France
| | - Olivier Kosmider
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Biologique, Hôpital Cochin, Paris, France.,Université de Paris, Institut Cochin, CNRSUMR8104, INSERM U1016, A Member of OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France
| | - Didier Bouscary
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France.,Université de Paris, Institut Cochin, CNRSUMR8104, INSERM U1016, A Member of OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France
| | - Nicolas Chapuis
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Biologique, Hôpital Cochin, Paris, France. .,Université de Paris, Institut Cochin, CNRSUMR8104, INSERM U1016, A Member of OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France.
| |
Collapse
|
29
|
Cluzeau T, Sebert M, Rahmé R, Cuzzubbo S, Lehmann-Che J, Madelaine I, Peterlin P, Bève B, Attalah H, Chermat F, Miekoutima E, Rauzy OB, Recher C, Stamatoullas A, Willems L, Raffoux E, Berthon C, Quesnel B, Loschi M, Carpentier AF, Sallman DA, Komrokji R, Walter-Petrich A, Chevret S, Ades L, Fenaux P. Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM). J Clin Oncol 2021; 39:1575-1583. [PMID: 33600210 PMCID: PMC8099409 DOI: 10.1200/jco.20.02342] [Citation(s) in RCA: 141] [Impact Index Per Article: 47.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
TP53-mutated (TP53m) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very poor outcome irrespective of the treatment received, including 40% responses (20% complete remission [CR]) with azacitidine (AZA) alone, short response duration, and a median overall survival (OS) of approximately 6 months. Eprenetapopt (APR-246), a novel first-in-class drug, leads to p53 protein reconformation and reactivates its proapoptotic and cell-cycle arrest functions.
Collapse
Affiliation(s)
- Thomas Cluzeau
- Cote d'Azur University, Hematology Department, Centre Hospitalier Universitaire of Nice, Nice, France.,Cote d'Azur University, Mediterranean Center of Molecular Medicine, INSERM U1065, Nice, France.,GFM
| | - Marie Sebert
- GFM.,Hematology Department, Hospital Saint Louis, Assistance Publique des Hopitaux de Paris (APHP), and Paris University, Paris, France
| | - Ramy Rahmé
- GFM.,Hematology Department, Hospital Saint Louis, Assistance Publique des Hopitaux de Paris (APHP), and Paris University, Paris, France
| | | | | | | | | | | | | | | | - Elsa Miekoutima
- Hematology Department, Hospital Saint Louis, Assistance Publique des Hopitaux de Paris (APHP), and Paris University, Paris, France
| | | | | | | | - Lise Willems
- GFM.,Hematology Department, Hospital Cochin, APHP, Paris, France
| | - Emmanuel Raffoux
- GFM.,Hematology Department, Hospital Saint Louis, Assistance Publique des Hopitaux de Paris (APHP), and Paris University, Paris, France
| | | | - Bruno Quesnel
- GFM.,Hematology Department, CHU of Lille, Lille, France
| | - Michael Loschi
- Cote d'Azur University, Hematology Department, Centre Hospitalier Universitaire of Nice, Nice, France.,Cote d'Azur University, Mediterranean Center of Molecular Medicine, INSERM U1065, Nice, France
| | | | - David A Sallman
- Hematology Unit, Moffitt Cancer Center and Research Institute, Tampa, FL
| | - Rami Komrokji
- Hematology Unit, Moffitt Cancer Center and Research Institute, Tampa, FL
| | | | - Sylvie Chevret
- SBIM, Hospital Saint Louis, APHP, and Paris University, Paris, France
| | - Lionel Ades
- GFM.,Hematology Department, Hospital Saint Louis, Assistance Publique des Hopitaux de Paris (APHP), and Paris University, Paris, France
| | - Pierre Fenaux
- GFM.,Hematology Department, Hospital Saint Louis, Assistance Publique des Hopitaux de Paris (APHP), and Paris University, Paris, France
| |
Collapse
|
30
|
Contejean A, Barreau S, Peyrard T, Bouscary D, Nataf J, Willems L. Hemophagocytic lymphohystiocytosis after haemolytic transfusion reaction due to anti-Wr a in a patient with myelodysplastic syndrome. Transfus Med 2020; 30:410-412. [PMID: 32893913 DOI: 10.1111/tme.12712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Accepted: 08/26/2020] [Indexed: 11/28/2022]
Affiliation(s)
- Adrien Contejean
- Service d'hématologie clinique, Hôpital Cochin, APHP, Paris, France.,Université de Paris, Paris, France
| | - Sylvain Barreau
- Université de Paris, Paris, France.,Service d'hématologie biologique, Hôpital Cochin, APHP, Paris, France
| | - Thierry Peyrard
- Institut National de la Transfusion Sanguine, Paris, France.,UMR_S1134 - Inserm, Université Paris Diderot, Paris, France
| | - Didier Bouscary
- Service d'hématologie clinique, Hôpital Cochin, APHP, Paris, France.,Université de Paris, Paris, France
| | - Joelle Nataf
- Laboratoire d'Immunologie Biologique/Unité d'Hémovigilance-Service de Gestion des Risques, Hôpital Cochin, APHP, Paris, France
| | - Lise Willems
- Service d'hématologie clinique, Hôpital Cochin, APHP, Paris, France
| |
Collapse
|
31
|
Contejean A, Jaffrelot L, Benaboud S, Treluyer J, Grignano E, Willems L, Gauzit R, Bouscary D, Hirt D, Kerneis S. Un modèle pharmacocinétique du méropénème chez le patient traité pour une hémopathie maligne. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
32
|
Alary AS, Vignon M, Carapito R, Halabi N, Willems L, Green A, Chapuis N, Heshmati F, Cuccuini W, Kaltenbach S, Radford-Weiss I, Kosmider O, Bouscary D, Bahram S, Rafii A, Tamburini J. Improvement of therapy-induced myelodysplastic syndrome by infusion of autologous CD34-positive hematopoietic progenitor cells without chemotherapy. Leuk Lymphoma 2020; 61:3259-3262. [PMID: 32856491 DOI: 10.1080/10428194.2020.1804562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Anne-Sophie Alary
- CNRS UMR8104, Institut Cochin, Université de Paris, INSERM U1016, Paris, France.,Hematology Laboratory, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Marguerite Vignon
- CNRS UMR8104, Institut Cochin, Université de Paris, INSERM U1016, Paris, France.,Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Raphael Carapito
- Laboratoire d'ImmunoRhumatologie Moléculaire, plateforme GENOMAX, INSERM UMR_S 1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), LabEx TRANSPLANTEX, Université de Strasbourg, Strasbourg, France
| | - Najeeb Halabi
- Stem Cell and Microenvironment Laboratory, Weill Cornell Medical College in Qatar, Education City, Qatar Foundation, Doha, Qatar
| | - Lise Willems
- CNRS UMR8104, Institut Cochin, Université de Paris, INSERM U1016, Paris, France.,Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Alexa Green
- CNRS UMR8104, Institut Cochin, Université de Paris, INSERM U1016, Paris, France.,Hematology Laboratory, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Nicolas Chapuis
- CNRS UMR8104, Institut Cochin, Université de Paris, INSERM U1016, Paris, France.,Hematology Laboratory, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Farhad Heshmati
- CNRS UMR8104, Institut Cochin, Université de Paris, INSERM U1016, Paris, France.,Apheresis Unit, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Wendy Cuccuini
- Hematology Laboratory, Saint Louis Hospital, AP-HP, Paris, France
| | | | | | - Olivier Kosmider
- CNRS UMR8104, Institut Cochin, Université de Paris, INSERM U1016, Paris, France.,Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Didier Bouscary
- CNRS UMR8104, Institut Cochin, Université de Paris, INSERM U1016, Paris, France.,Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Seiamak Bahram
- Laboratoire d'ImmunoRhumatologie Moléculaire, plateforme GENOMAX, INSERM UMR_S 1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), LabEx TRANSPLANTEX, Université de Strasbourg, Strasbourg, France
| | - Arash Rafii
- Stem Cell and Microenvironment Laboratory, Weill Cornell Medical College in Qatar, Education City, Qatar Foundation, Doha, Qatar
| | - Jerome Tamburini
- CNRS UMR8104, Institut Cochin, Université de Paris, INSERM U1016, Paris, France.,Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| |
Collapse
|
33
|
Contejean A, Jaffrelot L, Benaboud S, Tréluyer JM, Grignano E, Willems L, Gauzit R, Bouscary D, Gana I, Boujaafar S, Kernéis S, Hirt D. A meropenem pharmacokinetics model in patients with haematological malignancies. J Antimicrob Chemother 2020; 75:2960-2968. [DOI: 10.1093/jac/dkaa275] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Accepted: 05/19/2020] [Indexed: 02/03/2023] Open
Abstract
Abstract
Background
Optimal dosing of antibiotics is critical in immunocompromised patients suspected to have an infection. Data on pharmacokinetics (PK) of meropenem in patients with haematological malignancies are scarce.
Objectives
To optimize dosing regimens, we aimed to develop a PK population model for meropenem in this population.
Methods
Patients aged ≥18 years, hospitalized in the haematology department of our 1500 bed university hospital for a malignant haematological disease and who had received at least one dose of meropenem were eligible. Meropenem was quantified by HPLC. PK were described using a non-linear mixed-effect model and external validation performed on a distinct database. Monte Carlo simulations estimated the PTA, depending on renal function, duration of infusion and MIC. Target for free trough concentration was set at >4× MIC.
Results
Overall, 88 patients (181 samples) were included, 66 patients (75%) were in aplasia and median Modification of Diet in Renal Disease (MDRD) CLCR was 117 mL/min/1.73 m2 (range: 35–359). Initial meropenem dosing regimen ranged from 1 g q8h to 2 g q8h over 30 to 60 min. A one-compartment model with first-order elimination adequately described the data. Only MDRD CLCR was found to be significantly associated with CL. Only continuous infusion achieved a PTA of 100% whatever the MIC and MDRD CLCR. Short duration of infusion (<60 min) failed to reach an acceptable PTA, except for bacteria with MIC < 0.25 mg/L in patients with MDRD CLCR below 90 mL/min/1.73 m2.
Conclusions
In patients with malignant haematological diseases, meropenem should be administered at high dose (6 g/day) and on continuous infusion to reach acceptable trough concentrations.
Collapse
Affiliation(s)
- A Contejean
- Service d’Hématologie, AP-HP, Hôpital Cochin, Paris, France
- Equipe mobile d’infectiologie, AP-HP, Centre Université de Paris—Cochin, Paris, France
| | - L Jaffrelot
- Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, Paris, France
| | - S Benaboud
- Université de Paris, Faculté de Médecine, Paris, France
- Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, Paris, France
| | - J -M Tréluyer
- Université de Paris, Faculté de Médecine, Paris, France
- Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, Paris, France
- CIC-1419 Inserm, Cochin-Necker, Paris, France
| | - E Grignano
- Service d’Hématologie, AP-HP, Hôpital Cochin, Paris, France
- Université de Paris, Faculté de Médecine, Paris, France
| | - L Willems
- Service d’Hématologie, AP-HP, Hôpital Cochin, Paris, France
| | - R Gauzit
- Equipe mobile d’infectiologie, AP-HP, Centre Université de Paris—Cochin, Paris, France
| | - D Bouscary
- Service d’Hématologie, AP-HP, Hôpital Cochin, Paris, France
- Université de Paris, Faculté de Médecine, Paris, France
| | - I Gana
- Université de Paris, Faculté de Médecine, Paris, France
- Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, Paris, France
| | - S Boujaafar
- Université de Paris, Faculté de Médecine, Paris, France
- Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, Paris, France
| | - S Kernéis
- Université de Paris, Faculté de Médecine, Paris, France
- Equipe mobile d’infectiologie, AP-HP, Centre Université de Paris—Cochin, Paris, France
| | - D Hirt
- Université de Paris, Faculté de Médecine, Paris, France
- Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, Paris, France
- INSERM, U1018, Université Paris-Sud, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
| |
Collapse
|
34
|
Roupie AL, Guedon A, Terrier B, Lahuna C, Jachiet V, Regent A, de Boysson H, Carrat F, Seguier J, Terriou L, Versini M, Queyrel V, Groh M, Benhamou Y, Maurier F, Ledoult E, Clech LL, D'Aveni M, Rossignol J, Galland J, Willems L, Chiche NJ, Peterlin P, Roux-Sauvat M, Parcelier A, Wemeau M, Lambert M, Belizna C, Puechal X, Swiader L, Cohen-Valensi R, Noc V, Dao E, Thepot S, de Frémont GM, Tanguy-Schmidt A, Koka AM, Bussone G, Philipponnet C, Konate A, Cavaille G, Guilpain P, Allain JS, Broner J, Solary E, Ruivard M, de Renzis B, Corm S, Baati N, Schleinitz N, Ponsoye M, Stamatoullas-Bastard A, Ades L, Dellal A, Tchirkov A, Aouba A, Fenaux P, Fain O, Mekinian A. Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. Semin Arthritis Rheum 2020; 50:879-884. [PMID: 32896704 DOI: 10.1016/j.semarthrit.2020.07.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2020] [Revised: 06/13/2020] [Accepted: 07/06/2020] [Indexed: 12/20/2022]
Abstract
INTRODUCTION Our objective was to evaluate characteristics, treatment and outcome of vasculitis associated with myelodysplastic syndrome (MDS) and chronic myelomonicytic leukemia (CMML) PATIENTS AND METHODS: Retrospective descriptive analysis of MDS/CMML-related vasculitis and comparison with MDS/CMML patients without dysimmune features. RESULTS Seventy patients with vasculitis and MDS/CMML were included, with median age of 71.5 [21-90] years and male/female ratio of 2.3. Vasculitis was diagnosed prior to MDS/CMML in 31 patients (44%), and after in 20 patients. In comparison with MDS/CMML without autoimmune/inflammatory features, vasculitis with MDS/MPN showed no difference in MDS/CMML subtypes distribution nor International Prognostic Scoring System and CMML-specific prognostic (IPSS/CPSS) scores. Vasculitis subtypes included Giant cell arteritis in 24 patients (34%), Behçet's-like syndrome in 11 patients (20%) and polyarteritis nodosa in 6 patients (9%). Glucocorticoids (GCs) were used as first-line therapy for MDS/CMML vasculitis in 64/70 patients (91%) and 41 (59%) received combined immunosuppressive therapies during the follow-up. After a median follow-up of 33.2 months [1-162], 31 patients (44%) achieved sustained remission. At least one relapse occurred in 43 patients (61%). Relapse rates were higher in patients treated with conventional Disease Modifying Anti-Rheumatic Drug (DMARDs) (odds ratio 4.86 [95% CI 1.38 - 17.10]), but did not differ for biologics (odds ratio 0.59 [95% CI 0.11-3.20]) and azacytidine (odds ratio 1.44 [95% CI 0.21-9.76]) than under glucocorticoids. Overall survival in MDS/CMML vasculitis was not significantly different from MDS/CMML patients without autoimmune/inflammatory features (p = 0.5), but acute leukemia progression rates were decreased (log rank <0.05). CONCLUSION This study shows no correlation of vasculitis diagnoses with subtypes and severity of MDS/CMML, and no significant impact of vasculitis on overall survival. Whereas conventional DMARDs seem to be less effective, biologics or azacytidine therapy could be considered for even low-risk MDS/CMML vasculitis.
Collapse
Affiliation(s)
- Anne Laure Roupie
- Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France Sorbonne Université, Paris, France; Sorbonne Universités, INSERM U938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
| | - Alexis Guedon
- Sorbonne Universités, INSERM U938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
| | - Benjamin Terrier
- Department of Internal Medicine - National Reference Center for Rare and Systemic Autoimmune Diseases, Assistance Publique - Hôpitaux deAP-HP, Hôpital Cochin, Université de Paris, Paris, France
| | - Constance Lahuna
- Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France Sorbonne Université, Paris, France; Sorbonne Universités, INSERM U938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
| | - Vincent Jachiet
- Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France Sorbonne Université, Paris, France; Sorbonne Universités, INSERM U938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
| | - Alexis Regent
- Department of Internal Medicine - National Reference Center for Rare and Systemic Autoimmune Diseases, Assistance Publique - Hôpitaux deAP-HP, Hôpital Cochin, Université de Paris, Paris, France
| | - Hubert de Boysson
- Department of Internal Medicine, CHU Caen, Avenue de la côte de nacre, 14033 Caen, France
| | - Fabrice Carrat
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP Sorbonne Université, Hôpital Saint Antoine, 75012 Paris, France
| | - Julie Seguier
- Department of Internal Medicine, Assistance Publique-Hôpitaux de Marseille, Hôpital La Timone, Marseille, France
| | - Louis Terriou
- Department of Internal Medicine, CHU Lille, Lille, France
| | | | | | - Matthieu Groh
- Department of Internal Medicine, National Referral Center for Hypereosinophilic Syndromes (CEREO), Foch Hospital, Suresnes, France
| | - Ygal Benhamou
- Department of Internal Medicine, CHU Rouen, Rouen, France
| | - Francois Maurier
- Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France
| | - Emmanuel Ledoult
- Department of Internal Medicine and Clinical Immunology, CHU Lille, Lille, France
| | | | - Maud D'Aveni
- Department of Hematology, CHU Nancy, Nancy, France
| | - Julien Rossignol
- Department of Hematology, Gustave Roussy Cancer Center, 94805, Villejuif, France
| | - Joris Galland
- Department of Internal Medicine, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France
| | - Lise Willems
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, 75014 Paris, France
| | - Noemie Jourde Chiche
- Department of Nephrology, Centre de Néphrologie et de Transplantation Rénale, Assistance Publique-Hôpitaux de Marseille, Hôpital La Conception, Marseille, France
| | | | | | - Anne Parcelier
- Department of Hematology, Centre Hospitalier Bretagne Atlantique, Vannes, France
| | | | - Marc Lambert
- Department of Internal Medicine, CHU Lille, Lille, France
| | - Cristina Belizna
- Department of Vascular Medicine, CHU d'Angers, UMR-CNRS 6015 INSERM 1083, Angers, France
| | - Xavier Puechal
- Department of Internal Medicine - National Reference Center for Rare and Systemic Autoimmune Diseases, Assistance Publique - Hôpitaux deAP-HP, Hôpital Cochin, Université de Paris, Paris, France
| | - Laure Swiader
- Department of Internal Medicine, Assistance Publique-Hôpitaux de Marseille, Hôpital La Timone, Marseille, France
| | - Rolande Cohen-Valensi
- Department of Internal Medicine, CH de Martigues Hôpital des Rayettes, Martigues, France
| | - Valérie Noc
- Department of Nephrology, CH Hyères, Hyères, France
| | - Emmanuel Dao
- Department of Nephrology, CH Hyères, Hyères, France
| | | | | | | | | | - Guillaume Bussone
- Department of Internal Medicine, Hôpital Antoine Béclère, Clamart, France
| | | | - Amadou Konate
- Department of Internal Medicine, CHU Montpellier, Montpellier, France
| | - Guilhem Cavaille
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, 75014 Paris, France
| | - Philippe Guilpain
- Department of Internal Medicine, CHU Montpellier, Montpellier, France
| | - Jean-Sébastien Allain
- Department of Internal Medicine and Clinical Immunology, CHU Lille, Lille, France; Pôle cardio vasculaire et métabolisme, CH Saint-Malo, Saint-Malo, France
| | - Jonathan Broner
- Department of Internal Medicine, CHU de Nîmes, Nîmes, France
| | - Eric Solary
- Department of Hematology, Gustave Roussy Cancer Center, 94805, Villejuif, France
| | - Marc Ruivard
- Department of Internal Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Benoit de Renzis
- Department of Hematology, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Sélim Corm
- Department of Hematology, Médipôle de Savoie, Charles Les Eaux, France
| | - Nadia Baati
- Department of Hematology, CH Strasbourg, Strasbourg, France
| | - Nicolas Schleinitz
- Department of Internal Medicine, Assistance Publique-Hôpitaux de Marseille, Hôpital La Timone, Marseille, France
| | - Matthieu Ponsoye
- Department of Internal Medicine, CHU Ambroise Paré, Boulogne- Billancourt, France
| | | | - Lionel Ades
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France
| | - Azeddine Dellal
- Department of Rheumatology, Montfermeil Hospital, 93370 Montfermeil, France
| | - Andrei Tchirkov
- Department of Medical Cytogenetics, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Achille Aouba
- Department of Internal Medicine, CHU Montpellier, Montpellier, France
| | - Pierre Fenaux
- Department of Medical Cytogenetics, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Olivier Fain
- Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France Sorbonne Université, Paris, France; Sorbonne Universités, INSERM U938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
| | - Arsène Mekinian
- Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France Sorbonne Université, Paris, France; Sorbonne Universités, INSERM U938, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
| | | |
Collapse
|
35
|
Roupie AL, de Boysson H, Thietart S, Carrat F, Seguier J, Terriou L, Versini M, Queyrel V, Groh M, Benhamou Y, Maurier F, Decaux O, d'Aveni M, Rossignol J, Galland J, Solary E, Willems L, Schleinitz N, Ades L, Dellal A, Samson M, Aouba A, Fenaux P, Fain O, Mekinian A. Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review. Autoimmun Rev 2019; 19:102446. [PMID: 31838164 DOI: 10.1016/j.autrev.2019.102446] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2019] [Accepted: 09/15/2019] [Indexed: 10/25/2022]
Abstract
INTRODUCTION Myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasms (MDS/MPN) can be associated with giant cell arteritis (GCA). In this nationwide study by the "French Network of dysimmune disorders associated with hemopathies" (MINHEMON) the objective was to evaluate characteristics, treatment and outcome of GCA MDS-MDS/MPN. PATIENTS AND METHODS Retrospective analysis of patients that presented a MDS or MDS/MPN associated with GCA. Treatment efficiency, relapse-free and overall survival of GCA MDS-MDS/MPN were compared to GCA alone. RESULTS Twenty-one patients with GCA MDS-MDS/MPN were included with median age 76 [42-92], M/F ratio 2.5, 8 MDS with multilineage dysplasia (38%), 4 chronic myelomonocytic leukemia (19%), at low or intermediate risk according to IPPS and IPSS-R. The prevalence of headaches, jaw claudication and anterior ischemic optic neuropathy was significantly lower in patients with GCA MDS-MDS/MPN compared to idiopathic GCA (14.3%, 0% and 0% versus 30%, 25%, and 25%, respectively; p < .05). Other clinical and histology findings were similar. All GCA patients received steroid therapy as first-line treatment. Complete or partial response was observed in 14 GCA MDS-MDS/MPN patients (66.7%), of whom 6 (28.6%) received combined immunosuppressive therapies (versus 10% of idiopathic GCA; p = .07). Relapse incidence was similar in the two groups. Steroid dependence was more frequent among GCA MDS-MDS/MPN patients (12 (57%) versus 18 (22.5%); p < .05). Relapse-free and steroid-free survivals were significantly decreased in GCA MDS-MDS/MPN patients (log rank 0.002 and 0.049 respectively), but not overall survival. CONCLUSION Characteristics of GCA MDS-MDS/MPN seem different than idiopathic GCA, with a distinct clinical phenotype and poorer outcome with a higher risk of steroid dependence and relapse.
Collapse
Affiliation(s)
- Anne Laure Roupie
- Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France Sorbonne Université, France; Sorbonne Universités, INSERM U938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
| | - Hubert de Boysson
- Department of Internal Medicine, CHU Caen, Avenue de la côte de nacre, 14033 Caen, France
| | - Sara Thietart
- Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France Sorbonne Université, France
| | - Fabrice Carrat
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Saint Antoine, F75012 Paris, France
| | - Julie Seguier
- Department of Internal Medicine, CHU Marseille, Marseille, France
| | - Louis Terriou
- Department of Internal Medicine, CHU Lille, Lille, France
| | | | | | - Matthieu Groh
- Department of Internal Medicine, National Referral Center for Hypereosinophilic Syndromes (CEREO), Foch hospital, Suresnes, France
| | - Ygal Benhamou
- Department of Internal Medicine, CHU Rouen, Rouen, France
| | - Francois Maurier
- Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France
| | - Olivier Decaux
- Department of Internal Medicine, CHU Rennes, Rennes, France
| | - Maud d'Aveni
- Department of Hematology, CHU Nancy, Nancy, France
| | - Julien Rossignol
- Department of Hematology, Gustave Roussy Cancer Center, 94805 Villejuif, France
| | - Joris Galland
- Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France
| | - Eric Solary
- Department of Hematology, Gustave Roussy Cancer Center, 94805 Villejuif, France
| | - Lise Willems
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, 75014 Paris, France
| | | | - Lionel Ades
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France
| | - Azeddine Dellal
- Department of Rheumatology, Montfermeil Hospital, 93370 Montfermeil, France
| | - Maxime Samson
- Department of Internal Medicine, CHU Dijon, Dijon, France
| | - Achille Aouba
- Department of Internal Medicine, CHU Caen, Avenue de la côte de nacre, 14033 Caen, France
| | - Pierre Fenaux
- Department of Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France
| | - Olivier Fain
- Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France Sorbonne Université, France; Sorbonne Universités, INSERM U938, Centre de Recherche Saint-Antoine (CRSA), Paris, France
| | - Arsène Mekinian
- Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France Sorbonne Université, France; Sorbonne Universités, INSERM U938, Centre de Recherche Saint-Antoine (CRSA), Paris, France.
| | | |
Collapse
|
36
|
Barreau S, Green AS, Dussiau C, Alary A, Raimbault A, Mathis S, Willems L, Bouscary D, Kosmider O, Bardet V, Fontenay M, Chapuis N. Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1‐tube panel strategy for diagnosis and prognosis of patients with MDS. Cytometry 2019; 98:226-237. [DOI: 10.1002/cyto.b.21843] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Revised: 08/02/2019] [Accepted: 08/19/2019] [Indexed: 11/09/2022]
Affiliation(s)
- Sylvain Barreau
- Assistance Publique‐Hôpitaux de Paris, Hôpitaux Universitaires Paris CentreService d'Hématologie Biologique Paris France
- Université de Paris, Institut Cochin, CNRS UMR8104INSERM U1016 Paris France
| | - Alexa S. Green
- Assistance Publique‐Hôpitaux de Paris, Hôpitaux Universitaires Paris CentreService d'Hématologie Biologique Paris France
| | - Charles Dussiau
- Assistance Publique‐Hôpitaux de Paris, Hôpitaux Universitaires Paris CentreService d'Hématologie Biologique Paris France
- Université de Paris, Institut Cochin, CNRS UMR8104INSERM U1016 Paris France
| | - Anne‐Sophie Alary
- Assistance Publique‐Hôpitaux de Paris, Hôpitaux Universitaires Paris CentreService d'Hématologie Biologique Paris France
- Université de Paris, Institut Cochin, CNRS UMR8104INSERM U1016 Paris France
| | - Anna Raimbault
- Assistance Publique‐Hôpitaux de Paris, Hôpitaux Universitaires Paris CentreService d'Hématologie Biologique Paris France
- Université de Paris, Institut Cochin, CNRS UMR8104INSERM U1016 Paris France
| | - Stephanie Mathis
- Assistance Publique‐Hôpitaux de Paris, Hôpitaux Universitaires Paris CentreService d'Hématologie Biologique Paris France
- Université de Paris, Institut Cochin, CNRS UMR8104INSERM U1016 Paris France
| | - Lise Willems
- Assistance Publique‐Hôpitaux de ParisHôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique Paris France
| | - Didier Bouscary
- Université de Paris, Institut Cochin, CNRS UMR8104INSERM U1016 Paris France
- Assistance Publique‐Hôpitaux de ParisHôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique Paris France
| | - Olivier Kosmider
- Assistance Publique‐Hôpitaux de Paris, Hôpitaux Universitaires Paris CentreService d'Hématologie Biologique Paris France
- Université de Paris, Institut Cochin, CNRS UMR8104INSERM U1016 Paris France
| | - Valerie Bardet
- Assistance Publique‐Hôpitaux de ParisHôpitaux Universitaires Paris Ile de France Ouest, Service d'Hématologie‐Immunologie‐Transfusion Boulogne France
- INSERM U1173Université Versailles Saint Quentin en Yvelines France
| | - Michaela Fontenay
- Assistance Publique‐Hôpitaux de Paris, Hôpitaux Universitaires Paris CentreService d'Hématologie Biologique Paris France
- Université de Paris, Institut Cochin, CNRS UMR8104INSERM U1016 Paris France
| | - Nicolas Chapuis
- Assistance Publique‐Hôpitaux de Paris, Hôpitaux Universitaires Paris CentreService d'Hématologie Biologique Paris France
- Université de Paris, Institut Cochin, CNRS UMR8104INSERM U1016 Paris France
| |
Collapse
|
37
|
Mondesir J, Alary AS, Sibon D, Willems L, Deau B, Suarez F, Hermine O, Fontenay M, Bouscary D, Kosmider O, Tamburini J. Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study. Br J Haematol 2019; 187:65-72. [PMID: 31215036 DOI: 10.1111/bjh.16045] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2019] [Accepted: 04/16/2019] [Indexed: 12/01/2022]
Abstract
The treatment of relapsed/refractory (R/R) acute myeloid leukaemia (AML) remains a challenge. Among salvage chemotherapy regimens, the clofarabine and cytarabine (CLARA) combination has been widely evaluated and has a favourable safety/efficacy balance. Predictive factors of efficacy in patients with R/R AML are unclear, particularly the impact of AML-related gene mutations. We report our single-centre experience on 34 R/R AML patients treated with CLARA, with a focus on the genetic characterization of our cohort. CLARA yielded a 47% response rate among this poor-prognosis AML population, while two patients (5·8%) died due to treatment-related toxicity. The two-year progression-free survival and overall survival rates were 29·4% and 35·3%, respectively. Nine patients (26%) had long-term response with a median follow-up of 39·5 months among the responders, of whom six underwent haematopoietic stem cell transplantation. Adverse karyotype did not correlate with response or survival, and secondary AML were more frequent among responders to CLARA, suggesting that this combination may successfully salvage R/R AML patients regardless of adverse prognostic markers. We also observed that a low mutational burden and absence of splice mutations correlated with prolonged survival after CLARA, suggesting that extensive genotyping may have prognostic implications in R/R AML.
Collapse
Affiliation(s)
- Johanna Mondesir
- Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Haematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Anne-Sophie Alary
- Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Haematology Laboratory, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - David Sibon
- Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Haematology Department, Necker Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Lise Willems
- Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Haematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Benedicte Deau
- Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Haematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Felipe Suarez
- Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Haematology Department, Necker Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Olivier Hermine
- Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Haematology Department, Necker Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Michaela Fontenay
- Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Haematology Laboratory, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Didier Bouscary
- Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Haematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Olivier Kosmider
- Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Haematology Laboratory, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Jerome Tamburini
- Faculté de Médecine Sorbonne Paris Cité, Université Paris Descartes, Paris, France.,Haematology Laboratory, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| |
Collapse
|
38
|
Somers A, Spinewine A, Spriet I, Steurbaut S, Tulkens P, Hecq JD, Willems L, Robays H, Dhoore M, Yaras H, Vanden Bremt I, Haelterman M. Development of clinical pharmacy in Belgian hospitals through pilot projects funded by the government. Acta Clin Belg 2019; 74:75-81. [PMID: 29708056 DOI: 10.1080/17843286.2018.1462877] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Objectives The goal is to develop clinical pharmacy in the Belgian hospitals to improve drug efficacy and to reduce drug-related problems. Methods From 2007 to 2014, financial support was provided by the Belgian federal government for the development of clinical pharmacy in Belgian hospitals. This project was guided by a national Advisory Working Group. Each funded hospital was obliged to describe yearly its clinical pharmacy activities. Results In 2007, 20 pharmacists were funded in 28 pilot hospitals; this number was doubled in 2009 to 40 pharmacists over 54 institutions, representing more than half of all acute Belgian hospitals. Most projects (72%) considered patient-related activities, whereas some projects (28%) had a hospital-wide approach. The projects targeted patients at admission (30%), during hospital stay (52%) or at discharge (18%). During hospital stay, actions were mainly focused on geriatric patients (20%), surgical patients (15%), and oncology patients (9%). Experiences, methods, and tools were shared during meetings and workshops. Structure, process, and outcome indicators were reported and strengths, weaknesses, opportunities, and threats were described. The yearly reports revealed that the hospital board was engaged in the project in 87% of the cases, and developed a vision on clinical pharmacy in 75% of the hospitals. In 2014, the pilot phase was replaced by structural financing for clinical pharmacy in all acute Belgian hospitals. Conclusion The pilot projects in clinical pharmacy funded by the federal government provided a unique opportunity to launch clinical pharmacy activities on a broad scale in Belgium. The results of the pilot projects showed clear implementation through case reports, time registrations, and indicators. Tools for clinical pharmacy activities were developed to overcome identified barriers. The engagement of hospital boards and the results of clinical pharmacy activities persuaded the government to start structural financing of clinical pharmacy.
Collapse
Affiliation(s)
- A. Somers
- Federal Public Service Health, Food Chain Safety and Environment, Federal Network Pharmacy & Therapeutics Committee – Advisory Working Group on Clinical Pharmacy, Belgium
- Clinical Pharmacy at Ghent University Hospital, Gent, Belgium
| | - A. Spinewine
- Federal Public Service Health, Food Chain Safety and Environment, Federal Network Pharmacy & Therapeutics Committee – Advisory Working Group on Clinical Pharmacy, Belgium
- Head of Clinical Pharmacy Service, Université catholique de Louvain, Louvain Drug Research Institute, Brussels, Yvoir, Belgium
| | - I. Spriet
- Federal Public Service Health, Food Chain Safety and Environment, Federal Network Pharmacy & Therapeutics Committee – Advisory Working Group on Clinical Pharmacy, Belgium
- Clinical Pharmacy Services, Leuven University Hospital, Leuven, Belgium
- Department of Pharmacological and Pharmaceutical Sciences, Clinical Pharmacology and Pharmacotherapy, University of Leuven, Leuven, Belgium
| | - S. Steurbaut
- Federal Public Service Health, Food Chain Safety and Environment, Federal Network Pharmacy & Therapeutics Committee – Advisory Working Group on Clinical Pharmacy, Belgium
- Research Group Clinical Pharmacology & Clinical Pharmacy (KFAR), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium
| | - P. Tulkens
- Federal Public Service Health, Food Chain Safety and Environment, Federal Network Pharmacy & Therapeutics Committee – Advisory Working Group on Clinical Pharmacy, Belgium
- Drug Development, Faculty of Pharmacy and Biomedical Sciences, Université catholique de Louvain, Bruxelles, Belgium
| | - J. D. Hecq
- Federal Public Service Health, Food Chain Safety and Environment, Federal Network Pharmacy & Therapeutics Committee – Advisory Working Group on Clinical Pharmacy, Belgium
- Head of Department Pharmacy of the CHU-UCL, Namur, Belgium
| | - L. Willems
- Federal Public Service Health, Food Chain Safety and Environment, Federal Network Pharmacy & Therapeutics Committee – Advisory Working Group on Clinical Pharmacy, Belgium
- Former Director of Pharmacy, University Hospital Leuven, Leuven, Belgium
| | - H. Robays
- Federal Public Service Health, Food Chain Safety and Environment, Federal Network Pharmacy & Therapeutics Committee – Advisory Working Group on Clinical Pharmacy, Belgium
- Former Director of Pharmacy, University Hospital Gent, Gent, Belgium
| | - M. Dhoore
- Federal Public Service Health, Food Chain Safety and Environment, Federal Network Pharmacy & Therapeutics Committee – Advisory Working Group on Clinical Pharmacy, Belgium
- Federal Public Service Health, Food Chain Safety and Environment, Lovendegem, Belgium
| | - H. Yaras
- Federal Public Service Health, Food Chain Safety and Environment, Federal Network Pharmacy & Therapeutics Committee – Advisory Working Group on Clinical Pharmacy, Belgium
- Federal Public Service Health, Food Chain Safety and Environment, Brussels, Belgium
| | - I. Vanden Bremt
- Federal Public Service Health, Food Chain Safety and Environment, Federal Network Pharmacy & Therapeutics Committee – Advisory Working Group on Clinical Pharmacy, Belgium
- Federal Public Service Health, Food Chain Safety and Environment, Brussels, Belgium
| | - M. Haelterman
- Federal Public Service Health, Food Chain Safety and Environment, Federal Network Pharmacy & Therapeutics Committee – Advisory Working Group on Clinical Pharmacy, Belgium
- Head of Service Quality of Health and Patient Safety, Federal Public Service Health, Food Chain Safety and Environment, Brussels, Belgium
| |
Collapse
|
39
|
Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J. High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. Leuk Lymphoma 2019; 60:2324-2327. [PMID: 30773115 DOI: 10.1080/10428194.2019.1577414] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- Louis Perol
- Hematology Department, Cochin Hospital , Paris , France.,Paris Descartes University , Paris , France
| | - Eric Grignano
- Hematology Department, Cochin Hospital , Paris , France.,Paris Descartes University , Paris , France
| | - Adrien Contejean
- Hematology Department, Cochin Hospital , Paris , France.,Paris Descartes University , Paris , France
| | - Lauris Gastaud
- Hematology Department, Antoine Lacassagne Cancer Center , Nice, France
| | - Marielle Legoff
- Hematology Department, Cochin Hospital , Paris , France.,Paris Descartes University , Paris , France
| | - Patricia Franchi
- Hematology Department, Cochin Hospital , Paris , France.,Paris Descartes University , Paris , France
| | - Bénédicte Deau-Fischer
- Hematology Department, Cochin Hospital , Paris , France.,Paris Descartes University , Paris , France
| | - Lise Willems
- Hematology Department, Cochin Hospital , Paris , France.,Paris Descartes University , Paris , France
| | - Didier Bouscary
- Hematology Department, Cochin Hospital , Paris , France.,Paris Descartes University , Paris , France
| | - Jerome Tamburini
- Hematology Department, Cochin Hospital , Paris , France.,Paris Descartes University , Paris , France
| |
Collapse
|
40
|
Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, Herbaux C, Roos‐Weil D, Chaoui D, Roussel X, Tricot S, Dupuis J, Dartigeas C, Bareau B, Bene MC, Baugier de Materre A, Leblond V. Bendamustine plus rituximab in newly‐diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol 2018; 186:146-149. [DOI: 10.1111/bjh.15718] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Kamel Laribi
- Department of Haematology Centre hospitalier Le Mans Le MansFrance
| | - Stéphanie Poulain
- Service d'Hématologie Cellulaire Centre de Biologie et Pathologie CHRU de Lille, France INSERM UMR 1172 IRCL LilleFrance
| | - Lise Willems
- Unité Fonctionnelle d'Hématologie Hôpital Cochin Assistance Publique Hôpitaux de Paris ParisFrance
| | - Fatiha Merabet
- Service Hématologie et Oncologie Hôpital André Mignot Centre Hospitalier de Versailles VersaillesFrance
| | - Ronan Le Calloch
- Service de médecine interne, maladies du sang et infectiologie Cornouaille Hospital Center QuimperFrance
| | | | - Charles Herbaux
- Service des Maladies du Sang Centre Hospitalier Universitaire (CHU) Lille LilleFrance
| | - Damien Roos‐Weil
- Haematology Department Sorbonne Universités UPMC Univ Paris 06, GRC‐11 Assistance Publique‐Hôpitaux de Paris University Hospital La Pitié Salpêtrière‐Charles Foix ParisFrance
| | - Driss Chaoui
- Service d'Hématologie Centre Hospitalier Universitaire BesançonFrance
| | - Xavier Roussel
- Service d'Hématologie Centre Hospitalier Universitaire BesançonFrance
| | - Sabine Tricot
- Service d'Hématologie Clinique CH de Valenciennes ValenciennesFrance
| | - Jehan Dupuis
- Lymphoid Malignancies Unit Groupe Hospitalier Henri Mondor‐Albert Chennevier APHP CreteilFrance
| | - Caroline Dartigeas
- Hématologie et Thérapie Cellulaire Hôpital Bretonneau CHU Tours ToursFrance
| | - Benoit Bareau
- Service d'hématologie et médecine interne Hôpital privé Sévigné, Vivalto Santé Cesson‐SévignéFrance
| | - Marie C. Bene
- Haematology Biology Nantes University Hospital NantesFrance
| | | | - Véronique Leblond
- Service d'Hématologie Hôpital Pitié Salpêtrière APHP Sorbonne Universités Paris France
| |
Collapse
|
41
|
Sui X, Xin T, Guo X, Jia H, Li M, Gao X, Wu J, Jiang Y, Willems L, Zhu H, Hou S. Genomic characterization and pathogenic study of two porcine reproductive and respiratory syndrome viruses with different virulence in Fujian, China. J Vet Sci 2018; 19:339-349. [PMID: 29284210 PMCID: PMC5974515 DOI: 10.4142/jvs.2018.19.3.339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Revised: 10/25/2017] [Accepted: 12/26/2017] [Indexed: 11/30/2022] Open
Abstract
Two strains of porcine reproductive and respiratory syndrome virus (PRRSV) were isolated in 2006 and 2016 and designated as FZ06A and FZ16A, respectively. Inoculation experiments showed that FZ06A caused 100% morbidity and 60% mortality, while FZ16A caused 100% morbidity without death. By using genomic sequence and phylogenetic analyses, close relationships between a Chinese highly pathogenic PRRSV strain and the FZ06A and FZ16A strains were observed. Based on the achieved results, multiple genomic variations in Nsp2, a unique N-glycosylation site (N33→K33), and a K151 amino acid (AA) substitution for virulence in the GP5 of FZ16A were detected; except the 30 AA deletion in the Nsp2-coding region. Inoculation experiments were conducted and weaker virulence of FZ16A than FZ06A was observed. Based on our results, a 30 AA deletion in the Nsp2-coding region is an unreliable genomic indicator of a high virulence PRRSV strain. The Nsp2 and GP5 differences, in addition to the virulence difference between these two highly pathogenic PRRSV strains, have the potential to be used to establish a basis for further study of PRRSV virulence determinants and to provide data useful in the development of vaccines against this economically devastating disease.
Collapse
Affiliation(s)
- Xiukun Sui
- Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China.,Molecular and Cellular Biology, Gembloux Agro-Bio Tech University of Liège, 5030 Gembloux, Belgium
| | - Ting Xin
- Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China
| | - Xiaoyu Guo
- Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China
| | - Hong Jia
- Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China
| | - Ming Li
- Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China
| | - Xintao Gao
- Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China
| | - Jing Wu
- Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China.,Molecular and Cellular Biology, Gembloux Agro-Bio Tech University of Liège, 5030 Gembloux, Belgium
| | - Yitong Jiang
- Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China
| | - L Willems
- Molecular and Cellular Biology, Gembloux Agro-Bio Tech University of Liège, 5030 Gembloux, Belgium
| | - Hongfei Zhu
- Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China
| | - Shaohua Hou
- Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China
| |
Collapse
|
42
|
Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine 2018; 31:174-181. [PMID: 29728305 PMCID: PMC6013781 DOI: 10.1016/j.ebiom.2018.04.018] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2018] [Accepted: 04/20/2018] [Indexed: 12/02/2022] Open
Abstract
Somatic mutations contribute to the heterogeneous prognosis of chronic myelomonocytic leukemia (CMML). Hypomethylating agents (HMAs) are active in CMML, but analyses of small series failed to identify mutations predicting response or survival. We analyzed a retrospective multi-center cohort of 174 CMML patients treated with a median of 7 cycles of azacitidine (n = 68) or decitabine (n = 106). Sequencing data before treatment initiation were available for all patients, from Sanger (n = 68) or next generation (n = 106) sequencing. Overall response rate (ORR) was 52%, including complete response (CR) in 28 patients (17%). In multivariate analysis, ASXL1 mutations predicted a lower ORR (Odds Ratio [OR] = 0.85, p = 0.037), whereas TET2mut/ASXL1wt genotype predicted a higher CR rate (OR = 1.18, p = 0.011) independently of clinical parameters. With a median follow-up of 36.7 months, overall survival (OS) was 23.0 months. In multivariate analysis, RUNX1mut (Hazard Ratio [HR] = 2.00, p = .011), CBLmut (HR = 1.90, p = 0.03) genotypes and higher WBC (log10(WBC) HR = 2.30, p = .005) independently predicted worse OS while the TET2mut/ASXL1wt predicted better OS (HR = 0.60, p = 0.05). CMML-specific scores CPSS and GFM had limited predictive power. Our results stress the need for robust biomarkers of HMA activity in CMML and for novel treatment strategies in patients with myeloproliferative features and RUNX1 mutations. TET2mut/ASXL1wt genotype predicts higher complete response rate and prolonged survival in CMML with hypomethylating agents. Conversely, RUNX1mut and CBLmut genotypes are associated with poorer outcome, independently of higher leukocyte count. CPSS and GFM prognostic scores showed modest performance when calculated at initiation of hypomethylating agents.
Somatic mutations contribute to the heterogeneous prognosis of chronic myelomonocytic leukemia (CMML). Hypomethylating agents (HMAs) are active in CMML. Response and survival in MDS and AML patients treated with HMAs is difficult to predict. We explore the predictive role of recurrent somatic mutations in a large retrospective cohort of 174 HMA-treated CMMLs. Consistent with MDS studies, we report a higher response rate in TET2mut/ASXL1wt patients. We also identify a CMML-specific molecular pattern (RUNX1mut or CBLmut) associated with shorter survival. Our results can inform treatment decision in CMML, for instance by using HMAs prior to transplant in TET2mut/ASXL1wt patients.
Collapse
Affiliation(s)
| | | | - Alessandro Sanna
- MDS Unit-Hematology, Università di Firenze AOU careggi, Firenze, Italy
| | - David Sallman
- Malignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, USA
| | - Catherine C Coombs
- Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Aline Renneville
- Laboratory of Hematology, Biology and Pathology Center, CHRU of Lille, Lille, France
| | - Olivier Kosmider
- Laboratory of Hematology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Thorsten Braun
- Department of Hematology, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Bobigny, France
| | - Uwe Platzbecker
- Department of Hematology and Oncology, University Hospital Carl Gustav Carus, Dresden, Germany
| | - Lise Willems
- Department of Hematology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Lionel Adès
- Department of Hematology, St Louis Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Diderot, Paris, France
| | - Michaela Fontenay
- Laboratory of Hematology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Raajit Rampal
- Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Eric Padron
- Malignant Hematology Department, H. Lee Moffitt Cancer Center, Tampa, FL, USA
| | - Nathalie Droin
- INSERM U1170, Gustave Roussy Cancer Center, Villejuif, France
| | - Claude Preudhomme
- Laboratory of Hematology, Biology and Pathology Center, CHRU of Lille, Lille, France
| | - Valeria Santini
- MDS Unit-Hematology, Università di Firenze AOU careggi, Firenze, Italy
| | | | - Pierre Fenaux
- Department of Hematology, St Louis Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Diderot, Paris, France
| | - Eric Solary
- INSERM U1170, Gustave Roussy Cancer Center, Villejuif, France; Department of Hematology, Gustave Roussy Cancer Center, University Paris Sud, Villejuif, France
| | - Raphael Itzykson
- Department of Hematology, St Louis Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Diderot, Paris, France; INSERM/CNRS UMR 944/7212, Saint-Louis Institute, Paris, France.
| |
Collapse
|
43
|
Birsen R, Blanc E, Willems L, Burroni B, Legoff M, Le Ray E, Pilorge S, Salah S, Quentin A, Deau B, Franchi P, Vignon M, Mabille L, Nguyen C, Kirova Y, Varlet P, Edjlali M, Dezamis E, Hoang-Xuan K, Soussain C, Houillier C, Damotte D, Pallud J, Bouscary D, Tamburini J. Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients. Oncotarget 2018; 9:16822-16831. [PMID: 29682187 PMCID: PMC5908288 DOI: 10.18632/oncotarget.24706] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2017] [Accepted: 02/25/2018] [Indexed: 12/18/2022] Open
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare topographic variant of diffuse large B-cell lymphoma (DLBCL). While prognostic scales are useful in clinical trials, no dynamic prognostic marker is available in this disease. We report here the prognostic value of early metabolic response by 18F-FDG PET scanner (PET) in 25 newly diagnosed immunocompetent PCNSL patients. Induction treatment consisted of four cycles of Rituximab, Methotrexate and Temozolamide (RMT). Based on patient's general condition, consolidation by high-dose Etoposide and Aracytine was given to responding patients. Brain MRI and PET were performed at diagnosis, after two and four cycles of RMT, and after treatment completion. Two-year progression-free (PFS) and overall survival (OS) were 62% and 74%, respectively for the whole cohort. Best responses after RMT induction were 18 (72%) complete response (CR)/CR undetermined (CRu), 4 (16%) partial response, 1 (4%) progressive disease and 2 (8%) stable disease. Response evaluation was concordant between MRI and PET at the end of induction therapy. Nineteen patients (76%) had a negative PET2. Predictive positive and negative values of PET2 on end-of-treatment (ETR) CR were 66.67% and 94.74%, respectively. We observed a significant association between PET2 negativity and ETR (p = 0.001) and longer PFS (p = 0.02), while having no impact on OS (p = 0.32). Two years PFS was 72% and 33% for PET2- and PET2+ patients, respectively (p < 0.02). PET2 evaluation may help to early define a subgroup of CR PCNSL patients with a favorable outcome.
Collapse
Affiliation(s)
- Rudy Birsen
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Hematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Estelle Blanc
- Department of Nuclear Medicine, Marie Lannelongue Hospital, Le Plessis Robinson, France
| | - Lise Willems
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Hematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Barbara Burroni
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Pathology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Marielle Legoff
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Hematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Emmanuelle Le Ray
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Hematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Sylvain Pilorge
- Hematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Sawsen Salah
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Ophtalmology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | - Benedicte Deau
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Hematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Patricia Franchi
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Hematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Marguerite Vignon
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Hematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Laurence Mabille
- Department of Nuclear Medicine, Marie Lannelongue Hospital, Le Plessis Robinson, France
| | - Charles Nguyen
- Department of Nuclear Medicine, Marie Lannelongue Hospital, Le Plessis Robinson, France
| | - Yioula Kirova
- Radiotherapy Department, Curie Institute, Paris, France
| | - Pascale Varlet
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Department of Neuropathology, Sainte-Anne Hospital, Paris, France
| | - Myriam Edjlali
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Department of NeuroImaging, Sainte-Anne Hospital, Paris, France
| | - Edouard Dezamis
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Department of Neurosurgery, Sainte-Anne Hospital, Paris, France
| | - Khê Hoang-Xuan
- Department of Neurology 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne Universités UPMC Universités Paris VI, IHU, ICM, Paris, France
| | - Carole Soussain
- Hematology Department, René Huguenin-Institut Curie Hospital, Saint Cloud, France
| | - Caroline Houillier
- Department of Neurology 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne Universités UPMC Universités Paris VI, IHU, ICM, Paris, France
| | - Diane Damotte
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Pathology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Johan Pallud
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Department of Neurosurgery, Sainte-Anne Hospital, Paris, France
| | - Didier Bouscary
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Hematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Jerome Tamburini
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Hematology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| |
Collapse
|
44
|
Birsen R, Willems L, Pallud J, Blanc E, Burroni B, Legoff M, Le Ray E, Pilorge S, Deau B, Franchi P, Vignon M, Kirova Y, Edjlali M, Houillier C, Soussain C, Varlet P, Dezamis E, Damotte D, Bouscary D, Tamburini J. Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients. Haematologica 2018; 103:e296-e299. [PMID: 29472354 DOI: 10.3324/haematol.2017.185843] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Rudy Birsen
- Paris Descartes University, Sorbonne Paris Cité, France.,Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), France
| | - Lise Willems
- Paris Descartes University, Sorbonne Paris Cité, France.,Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), France
| | - Johan Pallud
- Paris Descartes University, Sorbonne Paris Cité, France.,Department of Neurosurgery, Sainte-Anne Hospital, Paris, France
| | - Estelle Blanc
- Nuclear Medicine, Marie Lannelongue Hospital, Plessis Robinson, France
| | - Barbara Burroni
- Paris Descartes University, Sorbonne Paris Cité, France.,Pathology Department, Cochin Hospital, AP-HP, Paris, France
| | - Marielle Legoff
- Paris Descartes University, Sorbonne Paris Cité, France.,Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), France
| | - Emmanuelle Le Ray
- Paris Descartes University, Sorbonne Paris Cité, France.,Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), France
| | - Sylvain Pilorge
- Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), France
| | - Benedicte Deau
- Paris Descartes University, Sorbonne Paris Cité, France.,Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), France
| | - Patricia Franchi
- Paris Descartes University, Sorbonne Paris Cité, France.,Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), France
| | - Marguerite Vignon
- Paris Descartes University, Sorbonne Paris Cité, France.,Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), France
| | - Yioula Kirova
- Radiotherapy Department, Curie Institute, Paris, France
| | - Myriam Edjlali
- Paris Descartes University, Sorbonne Paris Cité, France.,Department of NeuroImaging, Sainte-Anne Hospital, Paris, France
| | - Caroline Houillier
- Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Sorbonne Universités UPMC Universités Paris VI, IHU, ICM, France
| | | | - Pascale Varlet
- Pathology Department, Sainte-Anne Hospital, Paris, France
| | - Edouard Dezamis
- Paris Descartes University, Sorbonne Paris Cité, France.,Department of Neurosurgery, Sainte-Anne Hospital, Paris, France
| | - Diane Damotte
- Paris Descartes University, Sorbonne Paris Cité, France.,Pathology Department, Cochin Hospital, AP-HP, Paris, France
| | - Didier Bouscary
- Paris Descartes University, Sorbonne Paris Cité, France.,Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), France
| | - Jerome Tamburini
- Paris Descartes University, Sorbonne Paris Cité, France .,Hematology Department, Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), France
| |
Collapse
|
45
|
Le Ray E, Belin L, Plancher C, Anract P, Babinet A, Dumaine V, Tamburini J, Deau Fischer B, Willems L, Magro L, Facon T, Leleu X, Bouscary D, Kirova YM. Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy. Leuk Lymphoma 2017; 59:1756-1758. [PMID: 29087212 DOI: 10.1080/10428194.2017.1393667] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Emmanuelle Le Ray
- a Service d'Hématologie , Hôpital Cochin, AP-HP , Paris , France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France
| | - Lisa Belin
- c Department of Biostatistics , Institut Curie , Paris , France
| | - Corine Plancher
- c Department of Biostatistics , Institut Curie , Paris , France
| | - Philippe Anract
- b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France.,d Service de chirurgie orthopédique , Hôpital Cochin, AP-HP , Paris , France
| | - Antoine Babinet
- b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France.,d Service de chirurgie orthopédique , Hôpital Cochin, AP-HP , Paris , France
| | - Valérie Dumaine
- b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France.,d Service de chirurgie orthopédique , Hôpital Cochin, AP-HP , Paris , France
| | - Jérôme Tamburini
- a Service d'Hématologie , Hôpital Cochin, AP-HP , Paris , France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France.,e Institut Cochin, Département Développement Reproduction Cancer , CNRS UMR8104, INSERM U1016 , Paris , France
| | - Bénédicte Deau Fischer
- a Service d'Hématologie , Hôpital Cochin, AP-HP , Paris , France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France
| | - Lise Willems
- a Service d'Hématologie , Hôpital Cochin, AP-HP , Paris , France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France
| | | | - Thierry Facon
- f Service d'Hématologie , CHRU Lille , Lille , France
| | - Xavier Leleu
- g Service d'hématologie , CHU de Poitiers , Poitiers , France
| | - Didier Bouscary
- a Service d'Hématologie , Hôpital Cochin, AP-HP , Paris , France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris , France.,e Institut Cochin, Département Développement Reproduction Cancer , CNRS UMR8104, INSERM U1016 , Paris , France
| | - Youlia M Kirova
- h Department of Radiation Therapy , Institut Curie , Paris , France
| |
Collapse
|
46
|
De Brognier A, Willems L. Viruses within animal genomes. REV SCI TECH OIE 2016; 35:133-42. [PMID: 27217174 DOI: 10.20506/rst.35.1.2423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Viruses and their hosts can co-evolve to reach a fragile equilibrium that allows the survival of both. An excess of pathogenicity in the absence of a reservoir would be detrimental to virus survival. A significant proportion of all animal genomes has been shaped by the insertion of viruses that subsequently became 'fossilised'. Most endogenous viruses have lost the capacity to replicate via an infectious cycle and now replicate passively. The insertion of endogenous viruses has contributed to the evolution of animal genomes, for example in the reproductive biology of mammals. However, spontaneous viral integration still occasionally occurs in a number of virus-host systems. This constitutes a potential risk to host survival but also provides an opportunity for diversification and evolution.
Collapse
|
47
|
Pilorge S, Harel S, Ribrag V, Larousserie F, Willems L, Franchi P, Legoff M, Biau D, Anract P, Roux C, Blanc-Autran E, Delarue R, Gisselbrecht C, Ketterer N, Recher C, Bonnet C, Peyrade F, Haioun C, Tilly H, Salles G, Brice P, Bouscary D, Deau B, Tamburini J. Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies. Leuk Lymphoma 2016; 57:2820-2826. [PMID: 27118302 DOI: 10.1080/10428194.2016.1177180] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare DLBCL location variant. We treated 76 PB-DLBCL patients by immuno-chemotherapy, resulting in an 84% sustained complete remission rate and a 78.9% survival over a 4.7-year median follow-up period. Ann Arbor stage IV and high age-adjusted international prognostic index were predictive of adverse outcome in univariate analysis. In multivariate analysis using a Cox model, only aa-IPI predicted long-term survival. While based on a limited number of cases, we suggested that radiotherapy may be useful as a consolidation modality in PB-DLBCL. We also suggested that positron emission tomography/CT scan should be interpreted with caution due to a persistent [18F]fluorodeoxyglucose [18FDG] uptake of bone lesions even after remission in some in PB-DLBCL patients. Our study based on a homogeneous cohort of PB-DLBCL patients confirmed the favorable outcome of this DLBCL variant and support the implementation of prospective clinical trials in this disease.
Collapse
Affiliation(s)
- Sylvain Pilorge
- a Hematology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France
| | - Stephanie Harel
- c Lymphoid Malignancies Unit , Saint Louis Hospital , Paris , France
| | | | - Frédérique Larousserie
- b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.,e Pathology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France
| | - Lise Willems
- a Hematology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France
| | - Patricia Franchi
- a Hematology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France
| | - Marielle Legoff
- a Hematology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France
| | - David Biau
- b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.,f Orthopedic Surgery Department , Cochin Hospital, AP-HP , Paris, France
| | - Philippe Anract
- b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.,f Orthopedic Surgery Department , Cochin Hospital, AP-HP , Paris, France
| | - Christian Roux
- b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France.,g Rhumatology Department , Cochin Hospital, AP-HP , Paris, France
| | - Estelle Blanc-Autran
- h Nuclear Medicine Department , Centre Medico-Chirurgical Marie-Lannelongue , Le Plessis-Robinson , France
| | | | | | | | - Christian Recher
- l Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole , Toulouse , France
| | - Christophe Bonnet
- m Département de Médecine, Service d'Hématologie Clinique , CHU Liège, Campus Universitaire du Sart-Tilman , Belgique
| | - Frederic Peyrade
- n Department of Oncology , Antoine-Lacassagne Center , Nice , France
| | - Corinne Haioun
- o Department of Hematology , Henri Mondor University Hospital , Créteil , France
| | - Hervé Tilly
- p Centre Henri-Becquerel , Université de Rouen , Rouen , France
| | - Gilles Salles
- q Centre Hospitalier Lyon Sud , Service d'Hématologie, Hospices Civils de Lyon , Lyon , France
| | - Pauline Brice
- c Lymphoid Malignancies Unit , Saint Louis Hospital , Paris , France
| | - Didier Bouscary
- a Hematology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France
| | - Bénédicte Deau
- a Hematology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France
| | - Jerome Tamburini
- a Hematology Department , Cochin Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) , Paris, France.,b Faculté de Médecine Sorbonne Paris Cité , Université Paris Descartes , Paris, France
| |
Collapse
|
48
|
Raimbault A, Bondu S, Pierre-Eugene C, Deudon C, Willems L, Frisan E, Chapuis N, Sapena R, Rouquette A, Kunz C, Fricke H, Kosmider O, Bardet V, Fontenay M. 104 APG101 (SOLUBLE CD95-FC) IMPROVES BFU-E GROWTH IN LOWER RISK MYELODYSPLASTIC SYNDROME WITH COLLAPSED ERYTHROPOIESIS: A PRECLINICAL STUDY. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30105-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Windmolders S, Willems L, Daniëls A, Linsen L, Fanton Y, Hendrikx M, Koninckx R, Rummens JL, Hensen K. Clinical-scale in vitro expansion preserves biological characteristics of cardiac atrial appendage stem cells. Cell Prolif 2015; 48:175-86. [PMID: 25630660 DOI: 10.1111/cpr.12166] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2014] [Accepted: 10/14/2014] [Indexed: 12/25/2022] Open
Abstract
OBJECTIVES Cardiac atrial appendage stem cells (CASCs) have recently emerged as an attractive candidate for cardiac regeneration after myocardial infarction. As with other cardiac stem cells, CASCs have to be expanded ex vivo to obtain clinically relevant cell numbers. However, foetal calf serum (FCS), which is routinely used for cell culturing, is unsuitable for clinical purposes, and influence of long-term in vitro culture on CASC behaviour is unknown. MATERIALS AND METHODS We examined effects on CASC biology of prolonged expansion, and evaluated a culture protocol suitable for human use. RESULTS In FCS-supplemented medium, CASCs could be kept in culture for 55.75 ± 3.63 days, before reaching senescence. Despite a small reduction in numbers of proliferating CASCs (1.37 ± 0.52% per passage) and signs of progressive telomere shortening (0.04 ± 0.02 kb per passage), their immunophenotype and myocardial differentiation potential remained unaffected during the entire culture period. The cells were successfully expanded in human platelet plasma supernatant, while maintaining their biological properties. CONCLUSIONS We successfully developed a protocol for long-term culture, to obtain clinically relevant CASC numbers, while retaining their cardiogenic potential. These insights in CASC biology and optimization of a humanized platelet-based culture method are an important step towards clinical application of CASCs for cardiac regenerative medicine.
Collapse
Affiliation(s)
- S Windmolders
- Laboratory of Experimental Hematology, Jessa Hospital, 3500, Hasselt, Belgium; Faculty of Medicine and Life Sciences, Hasselt University, 3590, Diepenbeek, Belgium
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Shiva Shankar TV, Willems L. Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network. Vascul Pharmacol 2014; 60:57-66. [PMID: 24445350 DOI: 10.1016/j.vph.2014.01.003] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Revised: 12/18/2013] [Accepted: 01/08/2014] [Indexed: 12/19/2022]
Abstract
In this review, we summarize the knowledge pertaining to the role of epigenetics in the regulation of angiogenesis. In particular, we show that lysine acetylation and cytosine methylation are important transcriptional regulators of angiogenic genes in endothelial cells. Lysine acetylation and cytosine methylation inhibitors idiosyncratically tune the transcriptome and affect expression of key modulators of angiogenesis such as VEGF and eNOS. Transcriptomic profiling also reveals a series of novel genes that are concomitantly affected by epigenetic modulators. The reversibility and overall tolerability of currently available epigenetic inhibitors open up the prospect of therapeutic intervention in pathologies where angiogenesis is exacerbated. This type of multitargeted strategy has the major advantage of overcoming the compensatory feedback mechanisms that characterize single anti-angiogenic factors.
Collapse
Affiliation(s)
- T V Shiva Shankar
- Molecular and Cellular Epigenetics (GIGA-Cancer) and Molecular Biology (GxABT), University of Liège (ULg), Liège, Belgium
| | - L Willems
- Molecular and Cellular Epigenetics (GIGA-Cancer) and Molecular Biology (GxABT), University of Liège (ULg), Liège, Belgium.
| |
Collapse
|